

BH



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 599 077 A2

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 93117519.4

⑮ Int. Cl. 5: **C12N 15/12, C12N 15/67,**
C12N 15/85, A61K 39/00,
A61K 48/00

⑭ Date of filing: 28.10.93

⑯ Priority: 29.10.92 US 968415

⑰ Applicant: **YEDA RESEARCH AND
DEVELOPMENT CO. LTD.**
P.O. Box 95
Rehovot 76100(IL)

⑰ Date of publication of application:

01.06.94 Bulletin 94/22

⑯ Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

⑰ Inventor: **Eisenbach, Lea**
Hanassi Harisohon 33
Rehovot 76303(IL)
Inventor: **Feldmann, Michael**
Beit Europa 27
Rehovot 76100(IL)

⑰ Representative: **VOSSIUS & PARTNER**
Siebertstrasse 4
D-81675 München (DE)

⑯ Anti-metastatic vaccine.

⑯ In accordance with the present invention, there is provided an antitumor cellular vaccine comprising tumor cells into which *c-fos* gene alone or together with *c-jun* have been inserted.

Additionally, the present invention provides a method of treating a patient suffering from cancer to prevent and/or inhibit the development of metastasis which comprises the administration of the above mentioned cellular vaccine.

Further, the present invention provides an antitumor vaccine comprising antigens expressed by *c-fos* gene alone or together with *c-jun* gene.

EP 0 599 077 A2

The present invention relates to anti-tumor cellular vaccines and more specifically to vaccines for providing immunotherapy by gene therapy to specifically control the generation of metastases.

Generally, there is a correlation between the expression of particular genes and HLA antigens as well as a correlation between the presence of certain tumor associated antigens (TAA) antigens and metastasis.

5 However, there has been a problem in linking genetic control to control of metastasis and its inhibitions.

By way of background, malignant tumors arise from a protracted sequence of events. Each step in the sequence of events creates an additional phenotypic aberration (1). Research indicates that tumor cells acquire the ability to metastasize through genetic variation (2). Expression or loss of expression of specific genes has been associated with the metastatic phenotype of various cell lines (3,4).

10 Under normal conditions, the metastatic cells are subjected to attack by the host defense system, as long as the host defense system is competent to do so. An effective immune response capable of eliminating dissemination of tumor cells is predominantly mediated by cytotoxic T lymphocytes (CTL), which recognize proteolitically derived, foreign peptide epitopes bound to class I antigens of the major histocompatibility complex (MHC class I).

15 The inventors of the present invention reported that down regulation of MHC class I antigen was correlated with high malignancy in human and murine tumors (5). Transfection of MHC class I genes, particularly of H-2K genes was shown to confer on these tumors high immunogenic and low metastatic phenotypes.

20 Applicants previously found by testing high and low metastatic tumor cell populations that there was a correlation between the relative expression of class I antigens on different clones of a malignant carcinoma and the expression of the *c-fos* protooncogene (6,7). Although the involvement of oncogenes in the cellular transformation and tumorigenesis is apparently well established, the connection between oncogene or protooncogene expression and the metastatic competence of tumor cells remains unclear. Hence, use of this system clinically has not yet been perfected.

25 Studies by applicants suggest that the *c-fos* protooncogene participates in the control of MHC gene expression as evidenced by the following three studies. First, the *c-fos* gene was expressed in cells of the low metastatic clones of the 3LL tumor at much higher levels, for both *c-fos* transcripts and proteins, relative to cells of the high metastatic clones of the 3LL tumor (7). When the high metastatic clones were treated by interferon, a transient elevation of *c-fos* expression was observed followed by induction of H-2 transcription and there was a quantitative correlation between *c-fos* and H-2 induction (7,8). Second, a temporal correlation was found between the expression of the MHC class I antigens and the expression of *c-fos* antigens in a number of differentiating leukemic cells (9). Human U937 histiocytic lymphoma cells and HL60 promyelocytic leukemia cells, induced to differentiate to macrophages by 12-O-tetradecanoyl-phorbol 13-acetate (TPA), show induction of *c-fos* and HLA expression (9). In murine erythroleukemic cells, dimethylsulfoxide induced a decline in constitutive *c-fos* levels that were accompanied by suppression of MHC expression (9). Thirdly, transfection with *c-fos* genes of the clone D122 (3LL carcinoma), was shown to induce the transcription of H-2K mRNA and to elevate the levels of H-2 proteins, but not some of the other gene products (7,8).

30 Of critical importance is the finding that the rapid and transient induction of *c-fos* following cell stimulation by different external signals has established *c-fos* as a key member of the immediate early gene family and has implicated Fos in signal transduction and the control of cell proliferation (11,12) as well as in cell differentiation (13). Moreover, the Fos gene acts as a transcriptional regulator whose function is dependent upon formation of heterodimeric complexes with members of the *jun* family of protooncogenes (*c-jun*, *junB*, and *junD*) and further it binds to AP-1 consensus sequences, to CREB sequences and to Ap1/CREB like variations in the regulatory regions of target genes (12,14,15,16).

45 Applicant herein provides evidence of control of the *c-fos* and the unexpected results obtained thereby, and in combination with *c-jun*, control and/or inhibit metastasis in human tumors and murine models which are strongly predictive of human response. Based on experimental evidence herein relating to human tumor cells and HLA genes, applicant has determined the ability of the transfection and expression 50 of particular genes to cause a dramatic decrease of tumorigenic and metastatic properties of various human tumors. Accordingly, applicant has derived an antitumor cellular vaccine and also a subcellular vaccine more specifically based on specifically expressed antigens for controlling tumorigenicity and metastatic properties of human tumor cells.

In accordance with the present invention, there is provided an antitumor cellular vaccine comprising 55 tumor cells into which a *c-fos* gene (SEQ ID No:6) alone or together with *c-jun* gene (SEQ ID No:3) has been inserted.

Additionally, the antitumor cellular vaccine of the present invention is suitable for treating a patient suffering from cancer to prevent and/or inhibit the development of metastasis.

Further, the present invention provides an antitumor vaccine comprising antigens expressed by the *c-fos* gene alone or together with the *c-jun* gene.

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

Figures 1A-1D show expression of *c-fos*, *c-jun*, *junB* and H-2K^b: (A) in low (L) and high (H) metastatic clones of 3LL and K1735 tumors, (B) in D122 clones (3LL) transfected by *c-fos*, *c-jun*, or both, (C) in clone F10.9 (B16) transfected by *c-fos* and *c-jun*, and (D) in clone A9 (3LL) transfected by *junB*;

Figures 2A-2C show cell surface expression of MHC class I: (A) on clone D122 (3LL) and transfectants, (B) on clone F10.9 (B16) and transfectants, and (C) on clone A9 (3LL) and *junB* transfectants, where direct RIA were performed as described in experimental procedures and results are the means of five experiments, Standard errors were under 10% of the means;

Figures 3A-3D show regulation of MHC class I promoter activity by *c-fos*, *c-jun* and *junB*: (A) schematic drawing of the K^b enhancer - promoter domain -365 to 0 and some of the known binding elements, (B) D122 (-), J67 (*c-jun*), F6A2 (*c-fos*) and D13 (*c-fos+c-jun*) stable transfectants were transiently transfected by H2 promoter - CAT constructs, or (C) by collagenase - CAT constructs, (D) the A9 (-) and AJB1 (*junB*) stable transfectants, were transiently transfected by the H2 promoter - CAT constructs;

Figures 4A-4C show specific DNA binding activity of nuclear proteins from *c-fos/c-jun* transfectants, to the K^b enhancer A: (A) nuclear extracts from D122 and F10.9 transfectants, untreated (-) or treated (+) with cycloheximide were reacted at room temperature with enhancer A oligonucleotide and separated on acrylamide gel as described in experimental procedures, (B) reactions were performed as in A, in presence of 25 molar excess of competitor 'AP1', (C) nuclear extracts were incubated with the rabbit anti-*fos*- β -galactosidase serum (+) or anti H-2D^b nonrelevant antibodies (c) for 60 minutes at 4°C, probes were added and incubation was continued as before;

Figures 5A-5C show the effect of *c-fos* / *c-jun* transfection on tumorigenicity and metastasis, (A) D122 transfectants were injected i.f.p. into C57BL (A) or CD1 nude (B) mice, wherein foot diameters were measured as described in experimental procedures and the mean of tumor diameter of 16 mice in two experiments are shown, (C) D122, F10.9, A9 and transfectants were injected i.v. into C57BL mice;

Figures 6A-6D show experimental metastatic potential of D122, F10.9, A9 and transfectants: (A,B) D122, F6A2, J67, FJ23, D13, D6 and D36 clones, (C,D) F10.9, F21, F33, F32 and F52 clones wherein lungs were removed, weighed, fixed in Bouin solution and clarified in 70% ethanol; and

Figure 7 shows lytic activity of CTLs induced by D122 and transfectants on homologous target cells, C57BL mice were immunized with D122(-), J67 (*c-jun*), F6A2 (*c-fos*) and D13 (*c-fos+c-jun*) as described and EL4 (C57BL thymoma) and Yac-1 (an NK sensitive target) were used as control target cells, and were not lysed by any of the effector cells.

Generally, the present invention provides an antitumor vaccine which when injected into an animal produces stimulation of cytotoxic T lymphocytes (CTL) to produce an antitumorigenic and antimetastatic immune response. That is, the injection of the antitumor vaccine, whether in cellular or subcellular form, results in cytotoxic T cell lymphocyte activation which reduces or inhibits the generation of metastasis.

Specifically, the antitumor vaccine preferably is a cellular vaccine comprising tumor cells into which *c-fos* gene (SEQ ID No:6) alone, or the *c-fos* gene in combination with the *c-jun* gene (SEQ ID No:3), have been inserted. The tumor cells can be selected from a wide variety of tumor cells, preferably cells which can be efficiently and easily transfected with the above mentioned genes. For example, the cells can be carcinoma or melanoma cells, as well as other types of tumor cells. These cells can be obtained from the patient per se or can be obtained from a cell line not originally from the patient.

Tumor cells from the patients will be obtained either from biopsies, surgical material such as primary tumors, metastases in lymph nodes or other metastases, or in some cases from pleural effluents. Cell lines will be selected on the basis of the type of cancer: melanoma lines for melanoma patients, breast carcinoma lines for breast carcinoma patients, etc. The cell lines will be HLA matched. This means that HLA typing will be performed on each patient and cell lines which match in at least one HLA class I allele to the patient will be selected. If necessary a combination of cell lines will be used, each matching in at least one allele to the patient HLA. For example, a patient that is A1; A2; B7; B27; CW3; CW4 may get a vaccine consisting of six cell lines, each carrying one of these alleles. Additionally, if TAA typing is available, a vaccine that is also matched by TAA screening and HLA screening will be constructed. Preferably, the tumor cells are derived from tumor cells having metastatic competence, those cells being at least similar if not the same as the cells already existing in the patient. Such cells are rendered ametastatic by methods described below.

The means for inserting the *c-fos* gene or the *c-fos* gene together with the *c-jun* gene can be accomplished by methods known in the art. For example, the cellular vaccine can comprise human tumor cells transfected with either the *c-fos* gene alone or both *c-fos* gene and *c-jun* gene. For example, the two genes, the *c-fos* gene and the *c-jun* gene, can be introduced into the tumor cells on a single 5 expression vector enabling constitutive production of the *c-fos* and *c-jun* gene products *in vivo*. Such methods have been previously detailed (7,23,44). Alternatively, the genes can be introduced into the tumor cells on different expression vectors enabling constitutive Production of the gene products *in vivo* by methods similar to those for the joint introduction, however, wherein each gene is transfected on an independent expression vector. Of course, consistent with the present invention, the *c-fos* gene alone can 10 be introduced into the tumor cells on an expression vector.

A mammalian expression vector is a DNA construct that contains elements necessary for expression in mammalian cells, such as promoters, enhancers, termination and poly A signals, splice signals and of course a cDNA or genomic structure of the gene of interest. Such vectors may also contain sequences that enable them to replicate in bacteria, in which case the plasmid will contain bacterial replication signals and 15 a gene for selection in a particular antibiotic such as an ampicillin-resistance gene.

Examples of expression vectors known in the art are genomic clones that contain autologous promoters and other processing signals (7); plasmid based vectors that do not carry a eukaryotic replicon, such as PTK2 (Wigeler, et al., 1977, *Cell* 11:223); PSV₂neo (Souther and Berg, 1982, *J. Mol. Appl. Genet.* 1:327); PRO-neo (Van Doren et al., 1984, *J. Virol.* 50:606); PSV₂gpt (Mulligan and Berg, 1980, *Science*, 209:1442), 20 and others known in the art; plasmid DNA expression vectors containing regulatory sequences from eukaryotic viruses such as simian virus 40 vectors (Solnick, D., 1981, *Cell* 24:135), bovine papilloma virus based vectors (Sarver et al., 1981, *Mol. Cell Biol.* 1:486), Epstein-Barr virus based vectors (Yates et al., 1985 *Nature* 313:812). In addition Retroviral vectors (Gilboa et al., 1986, *Biotechniques* 4:504), Adenovirus (Berkner K.L., 1988, *Biotechniques* 6:616), and Vaccinia virus (Fuerst et al., 1987, *Mol. Cell Biol.* 7:2538) 25 which are used as infectious particles but do not replicate in the recipient cell because of structural manipulations can be used.

With some expression vectors, such as retroviral vectors or adenovirus based vectors, the structure of the vector also suggests the method of gene transfer (infection). With other expression vectors, different gene transfer methods, which are the methods of introduction of DNA containing the expression vector into 30 the target cells, are used. Examples of gene transfer methods are: calcium phosphate (40), Lysosomes (46), DEAE Dextran (47), Polybrene (48), Protoplast fusion (49), and others known in the art.

In each of the above mentioned methods, gene transfer is performed before cell inactivation, if the cells are to be inactivated.

Preferably, the tumor cells used for the antitumor cellular vaccine are inactivated, although inactivation 35 is not necessary in all instances. Inactivation of the tumor cells is preferably performed by irradiation with gamma source at 3,000 to 10,000 Rad or by treatment with mitomycin C at concentrations of 30 to 100 μ g/ml for one hour (50). An alternative is to utilize both treatments to insure inactivation of the tumor cells (51). Of course, other methods known in the art, such as fixation in glutaraldehyde (0.1 to 1%) for 5 to 30 minutes may also be used (52).

40 The *c-fos*, and *c-jun* genes are preferably cloned from cDNA libraries as set forth below under the Methods section. The *c-fos* + *c-jun* fused plasmid is described below also. The preferred method of transfection is described below under "preparation of stable transfecants". However, alternative methods can be used such as using the *c-fos* (SEQ ID No:6) and *c-jun* (SEQ ID No:3), both of human origin under the control of various promoters, such as the viral long term repeats (LTR) of various origins, under the 45 control of a β actin promoter, or under strong promoters of enzymes, such as DNA polymerase type III as known in the art (53).

Preferably, the vaccine is formulated as an injection. The vaccine can contain inactivated tumor cells, inactivated as described above, in a saline or phosphate buffered saline. Preferably, no adjuvants would probably be required although alternative methods of preparation can include adjuvants such as BCG (54) 50 or Alum (55), may be considered for use. Intactness of cells may be important for antigen presentation and cytokine release. Adjuvants usually cause cell lysis, for example Freund's complete adjuvant (56).

Preferably, the vaccine would include 1×10^6 to about 1×10^9 transfected tumor cells. Such dosages in 55 human patients would be monitored either by skin tests or by reactivity of lymphocytes in one of the following methods: 1) nontransfected and transfected cells after inactivation are intradermally injected into the thigh or upper arm of the patient and DTH activity is measured by diameter of both the erythema and induration at 24 and 48 hours. Such instances would normally be negative. The patient is vaccinated and retested every two to four weeks. Maximal DTH is an indication for sufficient vaccination. 2) Blood can be drawn from the patient before vaccination. White blood cells are separated and viably frozen. Similar

samples are taken at various time points after vaccination and booster injections. The ability of the white blood cells from different stages of vaccination to lyse nontransfected and transfected cells is measured in a CTL (cytotoxic T-lymphocyte) assay (57). Stabilization of the lytic activity is a measure for maximum vaccination.

5 The antitumor vaccine made in accordance with the present invention need not necessarily be a cellular vaccine, what is critical is that the vaccine include immunogenically competent HLA antigens derived from the expression of the *c-fos* gene alone or together with the *c-jun* gene and immunogenic tumor associated antigen (TAA) derived peptides. Such preparations can be made from cell membrane preparations of the transfected tumor cells. The difficulty of this approach is that such membrane preparations can
10 hide the antigens depending upon the folding of the membranes. However, such vaccines have been made in the art for other preparations (58).

The vaccines of the present invention are suitable for the treatment of a patient suffering from cancer, the treatment preventing and/or inhibiting the development of metastasis.

Generally, this treatment includes a step of administering to the patient the vaccine described above.
15 More specifically, the patient would be treated as follows. First, cells from the primary tumor of the patient would be removed by biopsy or surgery. As discussed above, an alternative approach would be to use cells derived from other patients. In either case, the cells would be dispersed in a medium, such as Dulbecco's modified eagle medium (DMEM), RPMI or other mediums used for the preparation of cellular vaccines. A vector, such as the vectors discussed above, is inserted into the cells. The vector would comprise the
20 human *c-fos* gene or the human *c-fos* and *c-jun* genes. During this step, the positive transfectants that are high expressers of *c-fos* and MHC class I genes can be selected either by an appropriate antibiotic (G418 if a neo resistant gene is present on the vector, (59) or by binding of anti-HLA antibodies and enrichment by a Fluorescence Activated Cell Sorter (FACS). The transfectants are inactivated as described above by gamma or x-ray irradiation and/or treatment with mitomycin C as described above. Finally, an
25 effective amount of inactivated tumor *c-fos* or *c-fos* and *c-jun* transfected cells is administered into the patient, preferably by injection. A highly immunogenic vaccine is thus obtained for preventing and/or inhibiting tumor metastasis in the patient.

The following experimental evidence provides a basis for utilization of the present invention and its effectiveness in decreasing and/or preventing metastasis. Further, experimental evidence demonstrates the
30 mechanism of action by which cytotoxic T lymphocytes (CTL) are activated to produce the immunogenic response.

EXPERIMENTAL PROCEDURES

35 TUMOR CELLS

Tumor cells were maintained in DMEM, 10% fetal calf serum, and supplements (6). The Lewis lung carcinoma (3LL) and the B16 melanoma (B16) are malignant tumors which originated spontaneously in C57BL/6 (H-2^b) mice (17,18). A9 and D122 are low and high metastatic clones, respectively, cloned from
40 the 3LL carcinoma cells by limiting dilution (6). The high metastatic line B16-F10 was selected from B16 by I.J. Fidler (17). F10.9 is a high metastatic single cell clone derived from the B16-F10 line (19). The primary K1735 melanoma arose in an inbred C3H/HeN mouse following a short exposure to U.V. irradiation, it was transplanted once into an immunosuppressed recipient and then established in culture (20). The low-metastatic line 16 and the high metastatic line M4 were selected from K1735 by I.J. Fidler (20).

45 ASSAYS FOR TUMORIGENICITY AND METASTASIS

C57BL/6J (Jackson Laboratories, Bar Harbor, Maine) or CD1 nude mice (Weizmann Institute Breeding Center) were injected with 2X10⁵ 3LL or B16 tumor cells and C3H/HeN (Jackson Laboratories, Bar Harbor,
50 Maine) mice were injected with 2X10⁵ K1735 tumor cells, intrafootpad (i.f.p.) in the right hindleg. To monitor tumor growth, the diameter of tumor bearing feet were measured every 1-3 days with calipers. When tumor diameter reached 8 mm, the tumor bearing foot was amputated. Survival and formation of spontaneous lung metastases was monitored at the time that mice became moribund. Experimental lung metastases were tested by injecting C57BL/6J or CD1 nude mice with 5X10⁵ 3LL or 5X10⁴ B16 tumor cells, and C3H/HeN mice with 5X10⁵ K1735 tumor cells, into the mouse tail vein. Mice were sacrificed 30-35 days later for D122, F10.9 and M4 (high metastatic) clones, and 65-70 days later for A9 (low metastatic) clones, and lungs were excised and weighted. Lung weights are the averages of three experiments. Maintenance and experimental procedures of mice were performed according to NIH guidelines.

GENE EXPRESSION

5 RNAs were prepared from 1-3 X 10⁸ cells propagated in tissue culture or treated with 10 μ g/ml of cycloheximide for one hour, by the method of Chirgwin (21). Northern blots were prepared from formaldehyde-containing agarose gels loaded with 30 μ g total RNA per lane as described (7) and assayed by hybridization to [³²P] labeled probes. The following probes were used: *c-fos* - 1.2 kbp HinclI-EcoRI fragment from the pBK28 fos plasmid (22), *c-jun* - 1.1 kbp EcoRI-PstI fragment from chJ-2 plasmid (23), *junB* - 1.2 kbp HinclI-Nde I fragment from RSVjunB plasmid (24), for H-2K - the H-2K specific 30-mer oligonucleotide which codes for amino acids 148-157 of the H-2K^b protein. This oligonucleotide crossreacts 10 with H-2K^k (26/30 nucleotides). For the β actin probe, a 4.3 kbp insert of pAC18.1 was used (25). Hybridizations were performed in 50% formamide at 42°. Blots were washed in 0.1SSC-0.2% SDS at 60°. Blots hybridized to oligonucleotide probes were washed in 0.5 SSC-0.2% SDS at 50°.

PLASMIDS AND CONSTRUCTS

15 The plasmids Psv-cJun (23), pBK28 (22) and RSVjunB (24) have been previously described and characterized by others. *c-fos+c-jun* fused plasmid (CON. 9) was constructed by ligation of a HindIII-NdeI fragment from Psv-cjun (containing SV40 early promoter, *c-jun* cDNA and SV40 polyadenylation signal) into HindIII linearized pBK28, *c-fos* expression vector, blunt ending and religation. The *c-jun* and 20 *c-fos* are transcribed from separate promoters (SV40 and LTR, respectively) and the construct contains two poly A addition signals. PUC-365-CAT was prepared by cloning of a BamHI-XbaI restriction fragment from pH-2CAT (39) into a Puc19 vector. PUC-142-CAT and PUC-190-CAT were subcloned from p138H-2K CAT and p190H-2K CAT, respectively, into Puc19 vector (26), p38-H-2K-CAT, the collagenase promoter-CAT constructs, -73COL-CAT and -60COL-CAT (32) and the β galactosidase containing expression vector 25 PCH110 (Pharmacia, Inc.) were described before by others.

PREPARATION OF STABLE TRANSFECTANTS

30 Transfections of *c-jun*, *junB*, *c-fos* or *c-fos+c-jun* (CON.9) expression vectors into the high metastatic clone D122 (3LL), transfection of *c-fos+c-jun* (CON.9) into the high metastatic clone F10.9 (B16) and the transfection of *junB* into the low metastatic clone A9 (3LL) were performed by the calcium phosphate technique, in cotransfection with a 1:9 or 1:19 ratio of PSV₂neomycin resistance gene (PSV₂neo) (40). Control transfection was done with PSV₂neo alone. To increase the efficiency of transfection, a 10 minute treatment with DMEM-15% DMSO (dimethylsulfoxide) was performed after incubation with 35 DNA precipitates. Colonies growing in 400 μ g/ml G418 (GIBCO) four weeks after transfection were expanded and analyzed for expression of the inserted genes by Northern blot analysis as described above. The selected D122 *c-fos* high expressor F6A3 clone was further supertransfected by the *c-jun* expression vector, in cotransfection with 1:9 ratio of pSV2 hygromycin B resistance plasmid (pSV₂hygro) and the selection was done in 200 μ g/ml hygromycin B containing media. Control transfecants carrying pSV₂neo or 40 pSV₂hygro show hybridization patterns, MHC class I expression and malignant properties equal to parental cells. (19)

CELL-SURFACE H-2 ANTIGENS

45 Protein A-purified monoclonal antibodies 20-8-4 (α K^b) and 28-14-8 (α D^b) (27) were iodinated by chloramine T by standard protocols. Five hundred ng of labeled antibody were mixed with 5X10⁵ freshly trypsinized cells in 0.1 ml phosphate-buffered saline (PBS) in BSA-coated tubes. Triplicate samples were incubated at 0° for 90 minutes. After four washings in PBS-0.5% bovine serum albumin (BSA) 0.02% sodium azide, samples were monitored in a gamma scintillation counter.

50 TRANSIENT EXPRESSION ASSAYS

55 The Chloramphenicol acetyl transferase (CAT) gene codes for an enzyme that transfers a labeled ¹⁴C acetyl or butyryl group from [¹⁴C] acetyl CoA or [¹⁴C] butyryl CoA to chloramphenicol. It serves as a "reporter gene": when the structural CAT gene is ligated to promoter sequences of various genes and these constructs are transfected (transiently or stably) into cells, one can measure the CAT activity in cell lysates and learn from the data about the activity of the promoter fused to CAT in the particular cell lines. There is almost no background in mammalian cells since CAT is a bacterial enzyme (41).

For transient assays, 1×10^6 cells were plated in 10cm dishes, 24 hours before DNA transfection. Cells were incubated for 12 hours with calcium phosphate-precipitated plasmid DNAs (20 μ g of the CAT derivative plus 4 μ g of pCH110) then, following a 10 minute DMSO (15%, 37°C) shock, the cells were rinsed once, reseeded with fresh medium and 24-48 hours later the cells were processed for enzymatic assays. CAT activity, using 30 μ g of total cell extract protein, was determined as described (41), and β -galactosidase activity was determined as described (42). Experiments were repeated at least three times. Activity of CAT was normalized to activity of β -galactosidase to correct for difference in transfection efficiency.

5 GEL RETARDATION ASSAY

10 Nuclear extracts were prepared from 10×10^6 cells and used in gel retardation assays as described (28). Protein concentration were determined using the Bradford method (60) and ranged from 4-7mg/ml. A synthetic double stranded 49 bp oligodeoxynucleotide containing the entire enhancer A was used as a probe. The sequence (SEQ ID No:8) of the enhancer A fragment is:

15
 GGCAGTGAGGTCAAGGGTGGGGAAAGCCCAGGGCTGGGATTCCCCATCT
 GTCACTCCAGTCCCCACCCCTTCGGGTCCCGACCCCTAAGGGTAGAGG
 -205 -154

20 The AP1/CREB like nonlabeled competitor oligonucleotide was used in the binding assay (indicated by the broken line above domain -205 to -186 containing the AP1 like binding site in enhancer A (from -203 to -197). A nonrelevant 19-mer nonlabeled competitor oligonucleotide was used as a control.

25 DNA-protein binding was conducted in 20 μ l volumes. The nuclear extract (3-5 μ g) was incubated with 3 μ g of poly(dI-dC) (Pharmacia Inc.) for 15 minutes at room temperature. Approximately 0.1pmol of 32 P-labeled DNA (~10,000 cpm) was added to the preincubated nuclear extract. Unlabeled competitor DNA was added to the binding reaction two minutes before the labeled oligomer. Rabbit anti-fos- β -galactosidase fusion protein antiserum (43), when used, was added to the nuclear extracts for one hour at 4°C, prior to 32 P-labeled DNA addition. No disruption of the nucleoprotein complex binding was observed when a control antisera was added to the extract. DNA-protein complexes were resolved on 4% polyacrylamide gel (39:1 acrylamide to bisacrylamide) in 0.4X TBE (1X TBE is 50 mM Tris-borate [pH 8.3] 1mM EDTA). The gels were dried and autoradiographed with intensifying screens at -70°C.

35 IN VITRO LYtic ACTIVITY (CTL) ASSAY

40 C57BL/6J mice were immunized intraperitoneal (i.p), three times at 7-day intervals, with 2×10^6 tumor cells, irradiated (5000 Rad) and mitomycin C treated (80 μ g/ml/5 $\times 10^6$ cells). Spleen cells were removed 10 days after the last immunization and restimulated *in vitro* for 5 days with irradiated cells (as before) at ratio of 20:1 (responders/stimulators). Spleen cells were seeded at 4×10^6 cells/ml, in RPMI medium containing 10% FCS, 0.4% combined antibiotics, 2 mM glutamine, 1mM sodium pyruvate, 1mM nonessential amino acids, 2 $\times 10^{-5}$ M β -mercaptoethanol and 10 mM Hepes pH 7.4. On day 5, stimulated spleen cells were separated on lymphocyte preparation medium (Cedarlane, Ontario), washed three times with PBS and suspended at a concentration of 5×10^6 cells/ml. Five thousand target cells labeled with 35 S-methionine (NEN) for 6 hours were suspended in 96 u-shaped wells and graded numbers of effector cells were added at E/T ratios of 100:1, 50:1, 25:1 and 12.5:1. Plates were incubated for 16 hours for D122 and *fos/jun* transfectant targets, and 5 hours for EL4 and Yac1 targets at 37°C, 5% CO₂. Microplates were spun at 1000 rpm for 10 minutes and 100- μ l aliquots of supernatant were transferred into tubes, mixed with 3 ml scintillation fluid and monitored in a β -counter. Spontaneous release was determined by incubation of labeled cells with medium alone; maximal counts were determined by incubating the same target cells with 100 μ l 0.1 NaOH. Spontaneous release was below 20% of maximal release. Specific release is reported as the mean of triplicates values.

RESULTS OF EXPERIMENTATION

EXPRESSION OF *c-fos*, *c-jun*, *junB* AND H-2K GENES IN MURINE TUMORS.

5 Low metastatic 3LL clones were characterized as high expressors of *c-fos* and MHC class I genes in contrast to high metastatic 3LL clones that express low levels of both genes (7,29). To determine whether this correlation could be extended to other murine tumor systems the steady state mRNA expression of *c-jun*, *junB*, *c-fos* and H-2K (MHC) genes was assayed in K1735 melanoma (30) and B16 melanoma (17) metastatic tumors as well as in the Lewis lung carcinoma (3LL).

10 Northern blot analysis of the high metastatic clones D122 (3LL), M4 (K1735) and F10.9 (B16), and the low metastatic clones A9 (3LL) and 16 (K1735) is shown in Figure 1 (A and C). Hybridization was performed at 42°C in 50% formamide and 10% dextran sulfate for 36 hours. Blots were washed in 0.1 SSC, 0.1% SDS at 60°C. Hybridization to β actin probe was included as a measure for equal levels of RNA in the samples. The typical 2.2 kb *c-fos*, 2.7 kb *c-jun* and 2.0 kb *junB* transcripts appear in high metastatic 15 D122 cells and at much higher levels in A9 (3LL) low metastatic cells (Figure 1A lanes 1-2). Thus the correlation observed before (6,7) between low metastatic potential and elevated expression of *c-fos* and H-2K is also observed for *c-jun* and to a lesser extent for *junB* expression. Cells of the low metastatic clone 20 16 (K1735) expressed high levels of the *c-jun*, *junB*, *c-fos* and H-2K transcripts (Figure 1A lane 4), while only minor levels of these transcripts were observed in cells of the high metastatic clones, M4 (K1735) Figure 1A lane 3) and F10.9 (B16) (Figure 1C lane 1). Several variants of the presumably low metastatic B16 line, F1 that were tested, were all high metastatic *in vivo* and show expression profiles similar to F10.9. Thus no direct correlation can be shown in the B16 tumor.

25 The differential expression of *junB* and *c-jun* in K1735 clones did not change after a cycloheximide (CHX) treatment, which is known to stabilize and superinduce *c-fos* and *c-jun* mRNA's (31). CHX treatment caused a significant induction of *c-jun* and *junB* mRNA's in clone 16 cells, but only a marginal elevation in the M4 cells (Fig. 1A panel 2 and 3, lanes 5-6). In accordance with H-2K mRNA levels, clone 16 cells manifested high levels of H-2K^k cell surface glycoproteins, as opposed to almost complete lack of H-2K^k antigens on the cell surface of M4 cells (data not shown). The expression of H-2D^k was similar between the two clones (data not shown).

30 EFFECT OF *c-jun*, *junB* AND *c-fos* TRANSFECTION ON EXOGENOUS AND ENDOGENOUS GENE EXPRESSION.

35 The correlation between *c-fos* and *c-jun* gene expression and the low metastatic phenotype observed in 3LL carcinoma and in K1735 melanoma clones, raised questions concerning the cause-effect relation between these phenomena. To investigate the possibility that *c-fos* + *c-jun* family of genes play a role in regulating MHC class I expression, low K^b expressing D122 (3LL) cells were transfected with *c-jun*, *junB*, *c-fos* or *c-jun* + *c-fos* plasmids. Plasmids Psv-c-jun which contain the mouse *c-jun* cDNA (SEQ ID No:1) under SV40 early promoter control, RSV-JunB which contains the mouse *JunB* cDNA under 40 an LTR control and pBK28 which contains the human *c-fos* (SEQ ID No:6) cDNA under *v-fos* promoter control were used. Cotransfection was carried out with PSV₂neo cDNA at 9:1 ratio and selection in neomycin (G418) followed.

45 The *c-jun* + *c-fos* transfections were done either by supertransfection of a *c-fos* positive D122 clone (F6A3), with *c-jun* and hygromycin-B resistance (psV2hygro) plasmids or by transfection of a *c-jun* + *c-fos* expression construct Con.9, which assures that *c-fos* and *c-jun* transfected genes would be integrated in a similar copy number and in the same place in the cell genome. The low K^b, D^b expressor clone F10.9 (B16), was also transfected with the *c-fos* + *c-jun* plasmid Con.9. Figure 1B demonstrates the expression patterns of the various D122 stable transfecants and the effect on expression of endogenous genes of the *fos* and *jun* family as well as on the expression of the endogenous H-2K genes. 50 Expression of endogenous *junB* is highly induced by *c-fos* and *c-jun* overexpression, as demonstrated on the Northern blots in Fig. 1B (panel 3). Interestingly the parental D122 cells express a 2.0 kb transcript while the *c-fos* and *c-jun* transfecants express a closely spaced *junB* mRNA doublet of 2.0 and 2.1 kb. This doublet is likely to represent the use of different polyadenylation sites (44). Notably, transfecants of *c-fos* + *c-jun* (clones FJ23 and D13) express less *junB* transcripts than transfecants of either *c-fos* or 55 *c-jun* alone.

The positive transcriptional regulation of the *junB* gene, by *c-jun* and *c-fos* has not been described before. However, the promoter of *c-jun* was shown to contain an AP1 binding site and *c-jun* (probably by Jun-Fos complex) is an efficient activator of its own expression (32). Since the gene for *junB* is structurally

related to *c-jun* (33) it is conceivable that it might be similarly regulated.

c-fos transcript is overexpressed in *c-fos* and in *c-fos + c-jun* transfected clones (Fig. 1B panel 1). Since endogenous and exogenous transcripts are of a similar size, it is not clear whether the exogenous *c-fos* expression or *c-fos + c-jun* coexpression, actually reduced the endogenous *c-fos* expression.

5 Unexpectedly *c-jun* transfected also show high levels of the 2.2 kb endogenous *c-fos* transcript (Fig. 1B panel 1).

Although repression of *c-fos* promoter, by the Fos protein has been demonstrated in NIH3T3 and HeLa cells (34), and this repression was enhanced by coexpression with *c-jun* (35), in several other cell systems, introductions of exogenous *c-fos* genes, did not down regulate the expression of the endogenous 10 *c-fos* gene (36).

Moreover, introduction of *c-fos* into ES cells and production of chimeric *c-fos* mice showed that in these ES cells, in the chimeric mouse tissues and in tumor derived cell lines from these mice, both endogenous and exogenous *c-fos* RNA as well as *c-jun* RNA were highly elevated (37).

This may possibly be the result of the distinct cellular environment in the different cell lines. It has been 15 previously suggested that the repression of *c-fos* is the result of *c-fos + c-jun* complex interaction with another cellular protein or alternatively Fos and Jun may act independently on the same or different target proteins (35). Thus, it may depend on the precise composition of the cellular proteins whether a repressing or an activating effect is achieved.

Increased levels of 2.7 kb endogenous *c-jun* transcripts are expressed in all *c-fos* transfected cells 20 (Fig. 1B panel 2). Induction of *c-jun* in D122 cells transfected with human or mouse genomic *c-fos* were also observed (unpublished results). Fig. 1B panel 2 also shows *c-jun* overexpression in *c-jun* and double transfected cells. *c-jun* was shown to transactivate its own promoter (32), and in addition, the transfected 25 *c-jun* cDNA (Psv-*c-jun*) is driven by the SV40 promoter, which contains two AP1 binding sites, and may also be positively regulated by *c-jun*. This can account for the very high mRNA *c-jun* observed in J67 and FJ23 cells.

To summarize, *c-fos* and *c-jun* transfections into D122 cells induced endogenous *junB* mRNA. In addition, *c-fos* or *c-jun* transfection resulted in a reciprocal transcriptional activation, namely, the *c-fos* transfected D122 cells showed increased levels of the endogenous *c-jun* transcripts and the *c-jun* transfected D122 cells showed an increase in the endogenous *c-fos* gene expression. A similar analysis of 30 the RNA from *junB* transfected clones did not reveal significant changes in endogenous *c-fos* or *c-jun* expression compared to the parental D122 cells (data not shown).

ELEVATED MHC CLASS I IN *c-fos* and *c-jun* TRANSFECTANTS, REDUCED H-2 IN *junB* TRANSFECTANTS.

35

Hybridization of RNA extracted from the various *c-jun*, *c-fos* and double transfected cell lines and the parental D122 clone to an H-2K^b specific probe is shown at Fig. 1B panel 4. All the transfectants that expressed high levels of *c-fos* and *c-jun* mRNA show transcriptional activation of the 1.8 kb endogenous H-2K^b mRNA. The highest H-2K mRNA expressor among these transfectants is clone D13 which contains 40 the fused *c-fos + c-jun* genes. Notably the D13 cells show the lowest levels of *junB* mRNA transflectants, 3 out of 12 *c-fos* transflectants and 11 out of 35 *c-fos + c-jun* double transflectants which did not express elevated *c-jun* and *c-fos* mRNA's, did not show activation of H-2K transcription (data not shown), while all *c-fos* and *c-jun* single and double positive clones showed elevated steady state levels of H-2 mRNA. The data shown in Figure 1C demonstrate similar results in F10.9 (B16 melanoma) cells, namely the positive 45 stable F10.9 *c-jun + c-fos* transfected cell lines (F52 and F21) manifest a marked transcriptional activation of the H-2K^b gene relative to the parental, low expressor F10.9 clone (Fig. 1C panel 3). The H-2K^b mRNA expression pattern in D122, *junB* transfected clones remained very low, similarly to the parental D122 phenotype (data not shown). To evaluate the increase in H-2 related proteins in the *c-fos* and *c-jun* 50 transfected D122 (3LL) and F10.9 (B16) clones, direct radioimmunoassays were performed using [¹²⁵I]-labeled monoclonal antibodies to H-2K^b and H-2D^b antigens (27). Two to nine fold elevated levels of H-2K^b and 1.2-7 fold elevated H-2D^b expression on the cell surface of *c-fos*, *c-jun* and double transfected cells was observed (Fig. 2A and B).

These results indicate that MHC (H-2K and H-2D) expression from endogenous genes can be induced by *c-fos* and *c-jun* transfection, either by single gene transfer or by cotransfection with both genes. In 55 contrast, the D122 *junB* transfected clones show a decrease in the H-2^b cell surface expression (data not shown).

To further examine the possibility that *junB* might down regulate MHC class I expression, the *junB* gene was transfected into the high H-2K^b, H-2D^b expressor A9 (3LL) clone. Figure 1D shows the hybridization of

RNA extracted from the highest *junB* expressor clone AJB1 and parental A9 clone cells to the specific *junB*, *c-jun*, *c-fos* and H-2K probes. Most of the exogenously expressed JunB seems to appear as a 2.1 kb transcript in a closely spaced *junB* mRNA doublet of 2.0 kb and 2.1 kb while the endogenous *junB* transcript is primarily of the 2.0 kb (Fig. 1D, panel 1). The H-2K hybridization of pattern (Fig. 1D panel 2) indicates a decrease in the H-2K^b steady state mRNA levels in the transfected cells, relative to the parental high H-2K^b expressor A9 cells.

No significant changes were observed in *c-fos* and *c-jun* expression following the *junB* transfection (Fig. 1D, panels 3 and 4). Hybridization to β actin probe showed that equal amounts of RNA were used (not shown). Figure 2C demonstrates the cell surface expression of H-2K and H-2D proteins in the *junB* transfected clones. A decrease of 40%-70% below control (A9) is observed for the H-2K^b molecules and of 10%-40% for the H-2D^b molecules in A9 *junB* transfectants (Fig. 2C).

ACTIVATION OF THE H-2 PROMOTER BY *c-fos* AND *c-jun*

To address the possible mechanism by which cJun, JunB and cFos proteins regulate H-2 expression, portions of the H-2K promoter were fused to the CAT gene and activities were monitored following transient transfections into the stable *jun(s)* and *c-fos* overexpressing cells.

The plasmids PUC-365-CAT, PUC-190-CAT, PUC-142-CAT and p38-H-2K-CAT (p365, p190, p142, and p38 in Fig. 3) were used which are different deletion constructs of the 5' flanking region from the protein cap site, fused to the CAT gene (see fig. 3A). At least three separate assays were performed with each transfect as described in experimental procedures. Kinetics between 1-30 hours were monitored. Enzyme activities are linear up to 20 hours. Activities at 15 hours, of one representative assay are described. The construct PCH110 (containing the β -galactosidase gene fused to the SV40 promoter) was cotransfected with each of the CAT plasmids as an internal control to transfection efficiency.

As shown in Figure 3B high cJun, cFos expression of the transfected cells resulted in a marked activation of the p365 construct. The activation magnitude correlated well with the induction of H-2K mRNA (Fig. 1B), and with the increase in H-2 related proteins on the cell surface (Fig. 2A) of the transfected clones. In contrast, transfection with p142 that contains enhancer B only (Fig. 3B) or with p38 that contains only the TATA box (data not shown), into parental D122 or *c-fos*, *c-jun* transfectants, yielded very low CAT activity. The lower activation of p190 compared to the activation of p365 in *c-fos* and/or *c-jun* expressor cells (Fig. 3B), indicates that the AP1 like binding sequence (-200 -193) plays a major role in the activation of H-2 by the cFos and cJun proteins. Yet the activation of the p190 construct in cJun and cFos/cJun expressors, relative to the nonexpressor D122, indicates that the domain downstream to -190 is also regulated by *c-jun* or *c-jun* + *c-fos*. This cannot be attributed to the AP1-like domain in enhancer B since the p142 construct is hardly active in all lines (Fig. 3B).

These data suggest that the region between -190 and -142 includes an additional target of activation by the Fos-Jun complex which is not directly mediated by an AP1-sites in the promoter, since the sequence between -190 -142 does not contain an obvious AP1 binding site. It is possible that another gene product that is regulated via TRE/AP1 is a regulator of the IRS, or of the NFkB binding domain (see Fig. 3A) or that the cJun or cFos proteins interact directly with one of the nuclear proteins that bind in the -190 -142 promoter domain (see also reference 38).

To verify that a classical AP1 enhancer is also activated in these cells, the constructs -73Col•CAT and -60Col•CAT were used which contain the collagenase promoter region from position -73 to +63 or -60 to +63 respectively, fused to CAT gene at position +63 (32). The two constructs differ from each other by the deletion of the AP1 sequence between -73 and -60 in the collagenase promoter. The basal level of CAT expression from these constructs in the absence of appropriate stimulating factors is usually very low. The CAT expression following transient transfections of -73Col•CAT (Fig. 3C) resembled the expression patterns observed with the p365 construct of the H-2 promoter (Fig. 3C), namely, exogenous cFos and cJun expressors stimulated expression from either promoters, relative to the basal D122 activity. The AP1 deletion mutant -60Col•CAT (Fig. 3C) showed a low activity in Fos and Jun expressor cells, similar to the activity in parental D122 cells.

PROTEIN BINDING TO ENHANCER A IN *c-fos/c-jun* TRANSFECTANTS.

Gel mobility shift assays were performed to analyze the binding properties of nuclear proteins from *c-fos* and *c-jun* overexpressing cells, to the oligodeoxynucleotide sequence of the entire enhancer A region (see Fig. 3A and experimental procedures). As shown by Figure 4A, extracts from the D122 cells show formation of four complexes (bands I-IV) with enhancer A. CHX treatment induces mostly band I. D122

transfection with *c-fos* alone, *c-jun* alone or both, shows elevated formation of complexes I and IV, and to a lesser extent of band II, as well as a decrease of the intensity of band III (Fig. 4A,B). The non-labeled 'AP1' oligonucleotide (that contains AP1/CREB and flanking AP2 sequences, see experimental procedures) competes with bands I-III, and to a lesser extent with band IV (Fig. 4B).

Formation of complexes III and IV seems to be temperature dependent, since preincubation of nuclear extract with anti-Fos antibody or a control antibody at 4°C for one hour prior to addition of the labeled probe decreased significantly bands III and IV. In addition, under these conditions band II seems to split into two distinct complexes, II and II' (Fig. 4C). Complex I, which is elevated by *c-fos/c-jun* transfection, is specifically inhibited by pretreatment of the nuclear extracts with anti-Fos antibodies, but not with an unrelated, cell surface antibody (anti H-2D^b). Complex II that is marginally affected by the *c-fos/c-jun* transfection, seems also to be inhibited by anti-Fos, while complex II' is not.

Nuclear complex profiles of F10.9(B16) melanoma cells, show quantitatively a different profile; complex I, II, and IV are hardly visible, and band III constitutes the major complex. Upon CHX treatment bands I and II are intensified. Again, transfection of *c-fos+c-jun* elevated complexes I, II and IV, and reduced complex III (Fig 4A). These experiments indicate that transfection with *c-fos/c-jun* or both, increase the binding of specific complexes to enhancer A, and that the Fos protein is a part of at least two of these complexes (I and II).

NEGATIVE REGULATION OF H-2 BY JunB DOES NOT REQUIRE THE AP1 BINDING SITE

The repression of H-2 cell surface expression of *JunB* transfectants (Fig. 2C) was well correlated with the reduced levels of H-2K mRNA (Fig. 1D). To delineate the target of the JunB negative regulation on H-2 promoter transient transfection of H-2 CAT constructs was performed into the constitutively JunB overexpressing cells (Fig. 2C). Fig. 3D shows that construct p365 which has the maximal basal activity in A9 (3LL) cells is repressed in the JunB expressor AJB1 cells to approximately 70% of the basal (A9) activity (Fig. 3D, compare lanes 1 and 2). The activity of p190, which is 60% of the activity of p365 in A9 cells (compare lanes 1 and 3), was almost completely abolished in the JunB expressor AJB1 cells (Fig. 3D, compare lanes 3 and 4). The construct p142 (Fig. 3B,3D), as well as p38 (not shown) were inactive in both cell lines.

The moderate repression of p365 activity in JunB A9 compared to the striking decrease of p190 activity suggests that the region -190 to -142 includes the major target for JunB transrepression. This would probably be an indirect target, due to lack of known AP1 binding sites in this region. In addition the region -365 to -190 seems to include a site that interferes actively with the JunB suppression of the H-2 promoter. Possibly, the binding of the cJun-cFos complex to the AP1 site at -200 -193, is capable of preventing (partially) the repression by JunB. A possible mechanism may involve competitive interactions between JunB, cJun and cFos.

MODULATION OF TUMORIGENIC AND METASTATIC POTENCY

Transfected clones were tested for their tumorigenic and metastatic properties in syngeneic C57BL/6 mice which are the original host strain of 3LL and B16 tumors.

Fig. 5A demonstrates the mean growth rates of local tumors from the parental D122 clone and from transfected cell lines. Mice were sacrificed at the time of death of control groups. Lung weights were evaluated as described in experimental procedures. Two independent experiments clearly indicated that the *c-jun* transfectants grew at similar rates to the parental, highly tumorigenic D122 cells. On the other hand, in mice inoculated with the *c-fos* transfectant, F6A2, the growth of the tumor was significantly slower ($p<0.005$) and in the groups that were inoculated with high expressor *c-fos+c-jun* transfectants (FJ23, D6, D13, D56) the tumors did not grow at all in 92% (45 out of 49) of the mice.

To test the ability of these D122 transfectants to metastasize spontaneously in C57BL/6 recipients, primary tumors were amputated when the tumor reached 8mm in diameter and formation of lung metastasis was monitored in moribund mice.

Mice in the control, D122 injected, group, as well as the *c-jun* transfected groups showed very high levels of metastases 65 to 70 days after injection (data not shown). Mice injected with *c-fos* transfectants showed similar levels of metastases 85 to 90 days after injection. In contrast, among mice in six groups injected with double transfectants, 95% were metastasis free 120 days after injection indicating that a complete eradication of tumor cells had occurred at the primary injection site.

Taken together, these spontaneous metastasis assays, which closely parallel the course of disease in human, suggest an absolute suppression of the parental tumorigenic and metastatic phenotype following *c-fos+c-jun* cotransfection. This was not due to intrinsic growth inhibitory effects on the cells, since in

vitro all transfecants proliferated at a rate similar to that of the parental cells (data not shown).

To test whether the nonmetastatic phenotype manifested by the *c-fos + c-jun* transfecants is due to their failure to grow in the foot pad or whether the reduction in metastatic potential will also be manifested by an experimental metastasis assay, these clones were injected intravenously to C57BL/6 mice. The mice 5 were sacrificed when the mice in the control D122 group showed signs of respiratory distress, generally 35 to 39 days after injection. The lungs were excised and metastatic loads were evaluated.

Figures 5C and 6 A-B show the results of two i.v. experiments. The results are consistent with results of the spontaneous (intra footpad) experiments. Both the parental D122 and the *c-jun* transfecants were 10 highly metastatic, the *c-fos* transfected group were of moderate metastatic potential and the double *c-fos + c-jun* transfecants were of low or nonmetastatic phenotype. Thus, low tumorigenicity and low metastatic potential were fully correlated for the D122 *c-fos + c-jun* transfecants. In randomly selected 15 3LL clones, no such correlation was previously observed between the high and low metastatic clones (6).

Consistent with the above results are also the experimental metastasis assays with the B16-F10.9, *c-fos + c-jun* transfected clones. As shown in Fig. 5C and 6C, the high expressors were of low metastatic 15 phenotype, as opposed to the high metastatic phenotype of the parental clone.

IMMUNOGENICITY OF THE *c-fos, c-jun* TRANSFECTANTS

To test *in vivo* whether the low metastatic phenotype of the double transfecants is the result of an 20 interaction with the host's T cell dependent immune system, tumorigenicity and metastasis assays were performed in CD1 nude mice which were deficient in thymic dependent mature T cells.

Fig. 5B shows the growth curves of *c-fos + c-jun* transfecants, of a *c-jun* transfecant, and of the 25 parental D122 clone. The growth of the double transfecants is similar to the growth rates of the *c-jun* transfecant in the nude mice. Interestingly, all types of transfecants grew slightly slower than the D122 cells in nude mice. These clones exhibited a high metastatic phenotype, both in spontaneous and experimental assays (data not shown). Thus, the regain of the tumorigenic and metastatic properties by the *c-fos + c-jun* transfecants suggests that the suppression of the parental phenotype manifested in the C57BL mice is a result of an elevated immunogenicity which is dependent on a mature T-cell reaction.

Further evidence to the acquired immunogenicity was observed when mice that had been injected by 30 the double transfecants and did not show growth of the primary tumor after 120-150 days (Fig. 5A) were reinjected, intrafootpad, with the parental, high metastatic, D122 cells. In groups previously injected by D13 or FJ23 cells, the D122 cells grew significantly slower than in the control group ($p<0.005$ compared to naive mice injected with D122 cells), while groups previously injected by D6 or D56 cells showed a smaller, less significant reduction of tumor growth (data not shown). These results suggest that the rejection of the 35 primary tumors created memory cells capable of interacting with a D122 challenge.

The correlation between CTL activity and the malignant phenotypes of the various transfecants were 40 tested. Figure 7 shows the autologous, *in vitro* lytic activity of CTLs elicited in C57BL mice by inactivated (irradiated) D122 clone, *c-fos* transfecant F6A2, *c-jun* transfecant J67 and *c-fos + c-jun* cotransfecant clone D13. *In vitro* resensitized splenocytes were reacted with homologous S^{35} -methionine labeled target 45 cells in 16 hours assays. Spontaneous release was under 20% of total release. Triplicate samples were under 5% mean error. Immunization of D122 and J67 elicits low levels of CTL against autologous D122 or J67. In contrast, immunization by the *c-fos* transfecants or by *c-fos + c-jun* cotransfecants, elicit higher levels of CTL, that lyse efficiently autologous targets. These data are in agreement with *in vivo* results, and indicate that CTL induction and sensitivity might be a major effector in inhibition of tumorigenicity and metastasis in these transfecants.

JunB TRANSFECTION CONVERTS LOW TO HIGH METASTATIC CELLS

The negative effect of *junB* transfection of MHC class I expression of A9 (3LL) cells raised the question 50 of the potential effect of *junB* on the metastatic potential. Thus, the *junB* A9 transfecants (AJB1 and AJB10) were tested for their tumorigenic and metastatic properties in syngeneic C57BL/6 mice. Spontaneous metastasis assays indicated that the local tumor in mice inoculated by the transfecants did not grow significantly faster than the parental A9 clone and no spontaneous metastases developed up to 150 days after amputation. Conversely, when injected directly into the vein, six out of seven mice from the AJB1 55 group developed metastases 65 days post injection. Thereafter all other mice were sacrificed. Three out of seven mice from the AJB10 group but none of the A9 parental group developed metastases before the cessation of the experiment. Figures 5C (right hand), and Figure 6D demonstrate the i.v. results; while parental A9 cells were nonmetastatic, *junB* transfecants were moderately (AJB10) or high (AJB1) meta-

static. Based on the previous result, the increase in the metastatic potency following *junB* transfection is a result of reduced immunogenicity and reduced susceptibility to T-cell lysis.

The above data provide clear evidence that *c-fos*, *c-jun* and *junB* over-expression suppress certain aspects of the cancer process in murine carcinoma and melanoma cells while transfection with *junB* induces a metastatic phenotype. Tumor progression and metastases is a highly complicated process dependent on positive and negative regulation of many genes. Expression of MHC class I genes, that is obligatory for production of cellular immunity, was shown to be a rate limiting step in metastasis of 3LL carcinoma (6), B16 melanoma, T10 sarcoma and a variety of other tumors (39). The data above show a link between expression of MHC class I and expression of *c-fos* and *jun* family genes.

10 The above results further show that vaccines of human tumors can be generated by transfer of MHC genes and particularly, with two parental MHC genes tailor made for the heterozygous HLA phenotype of each patient. A simpler approach is to activate the expression of the endogenous MHC genes of each heterozygous tumor. This was achieved in accordance with the above experimental data by transfecting tumor cells with the *c-fos* and *c-jun* genes or the *c-fos* gene alone. This is based on conclusions drawn 15 from the data wherein the nonmetastatic H-2K expression clones of the 3LL tumor coexpress the *c-fos* gene. Accordingly, the question is raised whether the expression of the two gene products is causally related and whether the *c-fos* gene is involved in the up regulation of MHC class I genes. Earlier studies (7,8) by applicants indicated that the application in culture of γ -Interferon to D122 cells induced the expression of H-2 genes. The above data demonstrates that following treatment with Interferon, first *c-fos* 20 transcripts were induced, followed by the appearance of H-2K transcripts. Transfection with *c-fos* gene, whether of mouse (SEQ ID No:5) or of human (SEQ ID No:6) origin, converted the H-2K nonexpressors to expressor cells. When such cells were transplanted to syngeneic recipients, the generation of metastasis was significantly reduced.

Other systems in which the *c-fos* was shown to control the expression of cellular genes indicated that 25 the *c-fos* protein does not bind by itself to promote a region, but rather forms through a leucine zipper heterodimers of *c-fos* and *c-jun*, *junB*, or *junD*. These heterodimers act as the nuclear effectors by binding to DNA consensus sequences. The data shows that transfection of tumor cells with *c-fos* induced *c-jun* and *junB* expression in reciprocally transfection with *c-jun* or *c-fos* expression. However, the *c-fos* 30 transfectants manifested a reduction, but not complete abolishment, of the metastatic phenotype. Cotransfection of D122 cells with *c-fos* and *c-jun* genes resulted in a significant coexpression of both genes and up- regulation of H-2 genes. When such double transfectants were then transplanted into syngeneic animals, they manifested a complete abolishment of their phenotype. In fact, even the local growth of the transfectants was significantly arrested.

It appears that the insertion of both the *c-fos* and *c-jun* genes resulted in the acquisition of a very 35 effective immunogenic potency. The increase in immunogenicity of double transfectants was not attributed just to the up-regulation of the H-2K expression, since the levels of the H-2K transcripts following *c-fos* transcription was similar to the levels induced following *c-fos* or *c-jun* gene transfer. It is possible that in the double transfectants, only the class I gene products were elevated. The expression of tumorous associated antigens or their process to cell surface peptides could also have been up-regulated following 40 transfection with the *c-fos* and *c-jun* genes. The complete abolishment of the metastatic phenotype due to the acquisition of potent immunogenic properties following transfection with the *c-fos* and *c-jun* gene was achieved also with the B16-F10.9 melanoma. Accordingly, the insertion of the *c-fos* and *c-jun* genes which control the expression of MHC class I genes is a useful strategy for the generation of cellular tumor vaccines made in accordance with the methods described above, avoiding the necessity to tailor-make 45 gene insertion in accordance with the individual MHC phenotypes.

Studies were conducted on a number of lines of human tumor cells. Applying differentiation inducers to such cells in culture, it was observed that whenever terminal differentiation was involved in the up-regulation of HLA expression, *c-fos* transcripts proceeded the appearance of the HLA transcripts. No *c-fos* expression was observed when the differentiation pattern did not involve HLA expression. It is therefore 50 believed that transfer of *c-fos* and *c-jun* genes into human neoplastic cells aiming at increased immunogenicity, is a modality for the generation of cellular vaccines of human tumors. Immunotherapy via gene therapy then comprises the surgical removal of the primary tumor, followed by vaccination with inactivated tumor cells into which *c-fos* and *c-jun* or *c-jun* alone had been inserted, resulting in highly immunogenic vaccine in accordance with the present invention.

55 The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims the invention may be practiced otherwise than as specifically described.

5 **REFERENCES**

1. Bishop, M.J. (1991). Molecular Themes in Oncogenesis. *Cell* 64, 235-248.
2. Baldwin, A.S., Sharp, P.A. (1987). Binding of a Nuclear Factor to a Regulatory Sequence in the Promotor of the Mouse H-2K^b Class I Major Histocompatibility Gene. *Mol. Cell. Biol.* 7, 305-313.
- 10 3. Hart, I.R., Goode, N.T., Wilson, R.E. (1989). Molecular Aspects of the Metastatic Cascade. *Biochem. Biophys. Acta* 989, 65-84.
4. Liotta, L.A., Steet, P.S. (1991). Cancer Metastasis and Angiogenesis: An imbalance of Positive and Negative Regulation. *Cell*, 64.
5. Eisenbach, L., Feldman, M. (1991). Tumor Cell Surface Determinants in Host Immunity Against Metastases. *Seminars in Cancer Biology* 2: 179-188.
- 15 6. Eisenbach, L., Segal, S., Feldman, M. (1983). MHC Imbalance and Metastatic Spread in Lewis Lung Carcinoma Clones. *Int. J. Cancer* 32, 113-120.
7. Kushtai, G., Barzilay, J., Eisenbach, L. (1988). The c-fos Protooncogene in Murine 3LL Clones Controls the Expression of MHC Genes. *Oncogene* 2, 119-128.
- 20 8. Kushtai, G., Feldman, M., Eisenbach, L. (1990). The c-fos Transfection of 3LL Tumor Cells Turns on MHC Gene Expression and Consequently Reduces Their Metastatic Competence. *Int. J. Cancer* 45, 1131-1136.
9. Barzilay, J., Kushtai, G., Eisenbach, L. (1987). Expression of Major Histocompatibility Class I Genes in Differentiating Leukemic Cells is Temporarily Related to Activation of c-fos Protooncogene. *Leukemia* 1, 198-204.
- 25 10. Miyazaki, J.I., Appella, E., Ozato, K. (1986b). Negative Regulation of the Major Histocompatibility Class I Gene in Undifferentiated Embryonal Carcinoma Cells. *Proc. Natl. Acad. Sci. USA* 83, 9537-9541.
11. Diamond, M.I., Miner, J.N., Yamamoto, K.R. (1990). Transcriptional Factor Interactions: Selectors of Positive or Negative regulation From a Single DNA Element. *Science* 249, 1266-1272.
- 30 12. Franza, B.R., Rauccher, F.J., Curran, T. (1988). The fos Complex and fos-related Antigens Recognize Sequence Elements That Contain AP-1 Binding Sites. *Science* 239, 1150.
13. Miller, R., Curran, T., Miller, D., Guilbert, L. (1985). Induction of c-fos During Myelomonocytic Differentiation and Macrophage Proliferation. *Nature* 314, 546-548.
- 35 14. Chiu, R., Boyle, W.J., Karin, M. (1988). The c-fos Protein Interacts With c-jun/AP-1 to Stimulate Transcription of AP1 Responsive Genes. *Cell* 54, 541-552.
15. Distel, R.J., Ro, H.S., Spigelman, B.M. (1987). Nucleoprotein Complexes That Regulate Gene Expression in Adipocyte Differentiation: Direct Participation of c-fos. *Cell* 49, 835-844.
- 40 16. Ryseck, R.P., Bravo, R. (1991). c-jun, jun B and jun D Differ in Their Binding Affinities to AP1 and CRE Consensus Sequences: Effect of FOS Proteins. *Oncogene* 6, 533-542.
17. Fidler, I.J. (1973). Selection on Sacsessive Tumor Lines for Metastasis. *Adv. Cancer Res.* 28, 149-150.
18. Poste, G., Fidler, I.J. (1978). The Pathogenesis of Cancer Metastasis. *Nature* 283, 139-146.
19. Porgador, A., Feldman, M., Eisenbach, L. (1989). H-2K Transfection of B16 Melanoma Cells Results in Reduced Tumorigenicity and Metastatic Competence. *J. Immunogen.* 16, 291-303.
- 45 20. Fidler, I.J., Hart, I.R. (1978). The Biologu of Cancer Invasion and Metastasis. *Adv. Cancer Res.* 28, 149-250.
21. Chirgwin, J.M., Przybyla, A.G., MacDonals, R.J., Rutter, W.J. (1974). Isolation of Biologically Active Ribonucleic Acid From Sources Enriched in Ribonuclease. *Biochem.* 18, 5294-5299.
- 50 22. Verma, I.M., Visvader, J., Lamph, W.W., DeTogni, P., Barber, J., Sassone-Corsi, P. (1988). Regulation of fos Gene: A Paradigm For Nuclear Oncogenes. *UCLA Symposia on Molecular and Cellular Biology*. New York, New Series.
23. Angel, P., Allegretto, E.A., Okino, S., Hattori, K., Karin, M. (1988a). Oncogen jun Encodes a Sequence Specific Trans-Activator Similar to AP-1. *Nature* 332, 166-171.
- 55 24. Ryder, K., Lanahan, A., Nathans, D. (1988). A Gene Activated by Growth Factors is Related to the Oncogene v-jun. *Proc. Natl. Acad. Sci. USA* 85, 1487-1491.
25. Nudel, U., Zakut, R., Shani, M., Neuman, S., Levi, Z., Yaffe, D. (1983). The Nucleotide Sequence of the Rat Cytoplasmatic b actin Gene. *Nucl. Acids Res.* 11, 1759-1771.

26. Baldwin, A., Sharp, P. (1988). Two Transcription Factors, NF- κ B and H2TF1, Interact With a Single Regulatory Sequence in the Class I Major Histocompatibility Complex Promoter. Proc. Natl. Acad. Sci. USA 85, 723-727.

27. Ozato, K., Sachs, D.H. (1981). Monoclonal Antibodies Reacting to Antigens of the H-2^b Haplotypes Reveal Genetic Control of Isotype Expression. J. Immunol. 126, 317-321.

5 28. Schreiber, E., Matthias, P., Muller, M., Schaffner, W. (1989). Rapid Detection of Octamer Binding Proteins With "Mini-Extracts", Prepared From a Small Number of Cells. Nucl. Acids. Res. 17, 6419.

29. Eisenbach, L., Hollander, N., Feldman, M. (1984). The Differential Expression of H-2K versus H-2D Antigens, Distinguishing Low Metastatic From High Metastatic Clones, is Correlated With the Immunogenic Properties of the Tumor Cells. Int. J. Cancer 34, 567-573.

10 30. Kripke, M.L. (1979). Speculations on the Role of Ultraviolet Radiation in the Development of Malignant Melanoma. J. Natl. Cancer Inst. 63, 541-548.

31. Angel, P., Imagawa, M., Karin, M. (1987). Phorbol Ester-Inducible Contain a Common cis Element Recognizable by a TPA Modulated Transacting Factor. Cell 49, 729-739.

15 32. Angel, P., Hattori, K., Karin, M. (1988b). The jun Proto-oncogene is Positively Autoregulated by its Product, jun/AP1. Cell 55, 875-885.

33. Ryder, K., Lanahan, A., Nathans, D. (1989). jun-D: A Third Member of the jun Gene Family. Proc. Natl. Acad. Sci. USA 86, 1500-1503.

20 34. Sassone-Corsi, P., Sisson, C., Verma, M. (1988). Transcriptional Autoregulation of the Proto-Oncogene fos. Nature 334, 314-319.

35. Lucibello, C.F., Lowag, C., Muller, R. (1989). Trans-Repression of the Mouse c-fos Promoter: A Novel Mechanism of fos-Mediated Transregulations. Cell 59, 999-1007.

25 36. Verma, I.M., Ransone, L.J., Visvader, J., Sassone-Corsi, P., Lamph, W.V. (1990a). fos-jun Conspiracy: Implications For the Cell. CIBA Found. Symp. 150 on Proto-Oncogenes in Cell Development, Chichester pp. 128-146.

37. Wang, Z.Q., Grigoriadis, A.G., Mohhle-Steinlein, U., Wagner, E.F. (1991). A Novel Target Cell For c-fos Induced Oncogenesis: Development of Chondrogenic Tumors in Embryonic Stem Cell Chimeras. EMBO J. 10, 2437-2450.

38. Israel, A., LeBail, O., Kourilsky, P. (1989). TNF Stimulates Expression of Mouse MHC Class I Genes 30 by Inducing an NF- κ B-like Enhancer Binding Activity which Displaced Constitutive Factors. EMBO J. 8, 3793-3800.

39. Israel, A., Kimura, A., Kieran, M., Yano, O., Kourilsky, P. (1987). A Common Positive Transacting Factor Binds to Enhancer Sequences in the Promoters of Mouse H-2 and β 2-Microglobulin Genes. Proc. Natl. Acad. Sci. 84, 2653-2657.

40 40. Graham, R., Van der Eb, A. (1983). A New Technique For the Assay of Infectivity of Human Adenovirus 5 DNA. Virol. 52, 456-467.

41. Schule, R., Muller, M., Kaltschmidt, C., Renkawitz, R. (1988). Many Transcription Factors Interact Synergistically With Steroid Receptors. Science 242, 1418-1430.

42. Nielsen, D.A., Chou, J., Mackrell, A.J., Casabandan, M.J., Steiner, D.F. (1983). Expression of a 45 Preproinsulin b-Galactosidase Gene Fusion in Mammalian Cells. Proc. Natl. Acad. Sci. USA 80, 5198-5202.

43. Muller, R., Wagner, E.F. (1984). Differentiation of F9 Tetratocarcinoma Stem Cells After Transfer of c-fos Proto-Oncogenes. Nature 311, 438-442.

44. Schutte, J., Viallet, J., Minna, J. (1989). jun-B Inhibits and c-fos Stimulates the Transforming and Transactivating Activities of c-jun. Cell 59, 987-997.

45. Fidler, I.J., Radinsky, R. (1990). Genetic Control of Cancer Metastasis. J. Natl. Cancer Inst. 82, 166-168.

46. Marnino R.J. and S. Gould-Fogeritz, 1988, biotechniques 6:682)

47. Vaheri A. and J.S. Pagano, 1965, Virology, 27:434)

50 48. Kawai S. and M. Nishizawa, 1984, Mol. Cell Biol. 4:1172

49. Schaffner, W. 1980, Proc. Natl. Acad. Sci. USA 77:2163

50. Porgador, A., Tzehoval, E., et al. 1992, IL6 gene transfection into 3LL tumor cells suppresses the metastatic phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:3679-3686

55 51. Plaksin, D., Gelber, C., Feldman M., Eisenbach L., Reversal of the metastatic phenotype of Lewis Lung Carcinoma cells following transfection with syngeneic H-2K^b gene. Proc. Natl. Acad. Sci. USA 85:4463-4467

52. Lider, O. et al., 1986, Vaccination againsts experimental autoimmune disease using T lymphocytes treated with hydrostatic pressure. Ann. N.Y. Acad. Sci. Part V, New Forms of Therapy, pp. 267-273

53. Sullenger, B.A., Lee, T.C., Smith, C.A., Gilboa, E., 1990, Expression of chimeric tRNA driven antisense transcripts renders NIH-3T3 cells highly resistant to moloney murine leukemia virus replication. Mol. Cell Biol. 10:6512-6523

54. Mastrangelo, M.G. et al., "Immunotherapy with microbial products", in Immunological approaches to cancer therapeutics", New York, John Wiley and Sons, p. 75, 1982

55. Bystryn, J.C. et al., Immunogenicity of polyvalent melanoma vaccines in human. Cancer 61:1065. 1988

10 56. Hollinshead A. et al., Pilot studies using melanoma tumor associated antigens (TAA) in specific active immunotherapy of malignant melanoma, Cancer 49:1387, 1982

57. Katz A., Feldman, M., Eisenbach, L. (1992) The Use of 35 Smithionine as a target cell label in long-term cytotoxic assays. J. Immunol. Meth. 49:255-260

15 58. Kokoahka, E.M., Michsche M. Active specific immunotherapy as adjuvant treatment for stage II malignant melanoma. Pigm. Cell (1979) 5,11

59. Gilboa et al. (1986)

60. Bradford M., Anal. Biochem., 72:248 (1976)

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(i) APPLICANT: Eisenbach, Lea
Feldman, Michael

10 (ii) TITLE OF INVENTION: Anti-Metastatic Vaccine

(iii) NUMBER OF SEQUENCES: 8

15 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Reising, Ethington, Barnard, Perry & Milton
(B) STREET: P. O. Box 4390
(C) CITY: Troy
(D) STATE: Michigan
(E) COUNTRY: U.S.A.
(F) ZIP: 48099

20 (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

25 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/968,415
(B) FILING DATE:
(C) CLASSIFICATION:

30 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Kohn, Kenneth I.
(B) REGISTRATION NUMBER: 30,955
(C) REFERENCE/DOCKET NUMBER: P-301(Weiz 28-92)

35 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (313) 689-3500
(B) TELEFAX: (313) 689-4071

35 (2) INFORMATION FOR SEQ ID NO:1:

40 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3135 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: mRNA
(B) LOCATION: 1..3135

50 (ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 917..1921

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5	CTGAGTGTGC GAGAGACAGC CTGGCAGGAG AGCGCTCAGG CAGACAGACA GACAGACGGA	60
	CGGACTTGGC CAACCCGGTC GGCCGCGGAC TCCGGACTGT TCATCCGTTT GTCTTCATT	120
	TCTCACCAAC TGCTTGGATC CAGCGCCCGC GGCTCCTGCA CCGGTATTTT GGGGAGCATT	180
10	TGGAGAGTCC CTTCTCCCGC CTTCCACGGA GAAGAAGCTC ACAAGTCCGG GCGCTGCTGA	240
	CAGCATCGAG AGCGGCTCCC GACCGCGCGA CGAAATAGGC GAGCGGCTAC CGGCCAGCAA	300
	CTTTCCTGAC CCAGAGGACC GGTAAACAAGT GGCCGGGAGC GAACTTTGC AAACTCTTC	360
	TGCGCCTTAA GGCTGCCACC GAGACTGTAA AGAAAAGGGA GAAGAGGAAC CTATACTCAT	420
15	ACCAAGTTCGC ACAGGCGGCT GAAGTTGGGC GAGCGCTAGC CGCGGCTGCC TAGCGTCCCC	480
	CTCCCCCTCA CAGCGGAGGA GGGGACAGTT GTTGGAGGCC GGGCGGCAGA GCCCGATCGC	540
	GGGCTTCCAC CGAGAAATTCC GTGACGACTG GTCAGCACCG CGGGAGAGCC GCTGTTGCTG	600
20	GGACTGGTCT GCGGGCTCCA AGGAACCGCT GCTCCCCGAG AGCGCTCCGT GAGTGACCGC	660
	GACTTTTCAA AGCTCGGCAT CGCGCGGGAG CCTACCAACG TGAGTGCTAG CGGAGTCTTA	720
	ACCCCTGGCGT CCCTGGAGCG AACTGGGGAG GAGGGCTCAG GGGGAAGCAC TGCCGTCTGG	780
	AGCGCACGCT CCTAAACAAA CTTTGTACAGA GAAGCAGGGA CGCGCGGGTA TCCCCCGCT	840
25	TCCCCGGCG CTGTTGGGGC CCCGAAACTT CTGCGCACAG CCCAGGCTAA CCCCCGGTGA	900
	AGTGACGGAC CGTTCT ATG ACT GCA AAG ATG GAA ACG ACC TTC TAC GAC	949
	Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp	
	1 5 10	
30	GAT GCC CTC AAC GCC TCG TTC CTC CAG TCC GAG AGC GGT GCC TAC GGC	997
	Asp Ala Leu Asn Ala Ser Phe Leu Gln Ser Glu Ser Gly Ala Tyr Gly	
	15 20 25	
	TAC AGT AAC CCT AAG ATC CTA AAA CAG AGC ATG ACC TTG AAC CTG GCC	1045
	Tyr Ser Asn Pro Lys Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala	
35	30 35 40	
	GAC CCG GTG GGC AGT CTG AAG CCG CAC CTC CGC GCC AAG AAC TCG GAC	1093
	Asp Pro Val Gly Ser Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp	
	45 50 55	
40	CTT CTC ACG TCG CCC GAC GTC GGG CTG CTC AAG CTG GCG TCG CCG GAG	1141
	Leu Leu Thr Ser Pro Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu	
	60 65 70 75	
	CTG GAG CGC CTG ATC ATC CAG TCC AGC AAT GGG CAC ATC ACC ACT ACA	1189
	Lau Glu Arg Leu Ile Ile Gln Ser Ser Asn Gly His Ile Thr Thr Thr	
	80 85 90	
45	CCG ACC CCC ACC CAG TTC TTG TGC CCC AAG AAC GTG ACC GAC GAG CAG	1237
	Pro Thr Pro Thr Gln Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln	
	95 100 105	
50	GAG CCC TTC GCC GAG GGC TTC GTG CGC GCC CTG GCT GAA CTG CAT AGC	1285
	Glu Gly Phe Ala Glu Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser	
	110 115 120	

	CAG AAC ACG CTT CCC AGT GTC ACC TCC GCG GCA CAG CCG GTC AGC GGG Gln Asn Thr Leu Pro Ser Val Thr Ser Ala Ala Gln Pro Val Ser Gly 125 130 135	1333
5	GCG GGC ATG GTG GCT CCC GCG GTG GCC TCA GTC GCA GGC GCT GGC GGC Ala Gly Met Val Ala Pro Ala Val Ala Ser Val Ala Gly Ala Gly Gly 140 145 150 155	1381
	GGT GGT GGC TAC AGC GCC AGC CTG CAC AGT GAG CCT CCG GTC TAC GCC Gly Gly Gly Tyr Ser Ala Ser Leu His Ser Glu Pro Pro Val Tyr Ala 160 165 170	1429
10	AAC CTC AGC AAC TTC AAC CCG GGT GCG CTG AGC AGC GGC GGT GGG GCG Asn Leu Ser Asn Phe Asn Pro Gly Ala Leu Ser Ser Gly Gly Gly Ala 175 180 185	1477
15	CCC TCC TAT GGC GCG GCG GGG CTG GCC TTT CCC TCG CAG CCG CAG CAG Pro Ser Tyr Gly Ala Ala Gly Leu Ala Phe Pro Ser Gln Pro Gln Gln 190 195 200	1525
	CAG CAG CAG CCG CCT CAG CCG CAC CAC TTG CCC CAA CAG ATC CCG Gln Gln Gln Pro Pro Gln Pro Pro His His Leu Pro Gln Gln Ile Pro 205 210 215	1573
20	GTG CAG CAC CCG CGG CTG CAA GCC CTG AAG GAA GAG CCG CAG ACC GTG Val Gln His Pro Arg Leu Gln Ala Leu Lys Glu Glu Pro Gln Thr Val 220 225 230 235	1621
	CCG GAG ATG CCG GGA GAG ACG CCG CCC CTG TCC CCT ATC GAC ATG GAG Pro Glu Met Pro Gly Glu Thr Pro Pro Leu Ser Pro Ile Asp Met Glu 240 245 250	1669
25	TCT CAG GAG CGG ATC AAG GCA GAG AGG AAG CGC ATG AGG AAC CGC ATT Ser Gln Glu Arg Ile Lys Ala Glu Arg Lys Arg Met Arg Asn Arg Ile 255 260 265	1717
30	GCC GCC TCC AAG TGC CGG AAA AGG AAG CTG GAG CGG ATC GCT CGG CTA Ala Ala Ser Lys Cys Arg Lys Arg Lys Leu Glu Arg Ile Ala Arg Leu 270 275 280	1765
	GAG GAA AAA GTG AAA ACC TTG AAA GCG CAA AAC TCC GAG CTG GCA TCC Glu Glu Lys Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser 285 290 295	1813
35	ACG GCC AAC ATG CTC AGG GAA CAG GTG GCA CAG CTT AAG CAG AAA GTC Thr Ala Asn Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val 300 305 310 315	1861
	ATG AAC CAC GTT AAC AGT GGG TGC CAA CTC ATG CTA ACG CAG CAG TTG Met Asn His Val Asn Ser Gly Cys Gln Leu Met Leu Thr Gln Gln Leu 320 325 330	1909
40	CAA ACG TTT TGAGAACAGA CTGTCAGGGC TGAGGGCAA TCGAAGAAAA Gln Thr Phe 335	1958
	AAAATAACAG AGACAAACTT GAGAACTTGA CTGGTTGCGA CAGAGAAAAA AAAAGTGTCC	2018
45	GAGTACTGAA GCCAAGGGTA CACAAGATGG ACTGGGTTGC GACCTGACGG CGCCCCCAGT	2078
	GTGCTGGAGT GGGAGGGACG TGGCGCCCT GGCTTGGCG TGGAGCCAGA GAGCAGCGGC	2138
	CTATTGGCCG CGAGACTTTG CGGACGGGCT GTGCCCGCGC GCGACCCAGAA CGATGGACTT	2198
50	TTCGTTAACAA TTGACCAAGA ACTGCATGGA CCTAACATTC GATCTCATTC AGTATTAAG	2258

5	GGGGTGGGA GGGGTTACAA ACTGCAATAG AGACTGTAGA TTGCTTCTGT ACTGCTCCTT	2318
	AACACAAAGC AGGGAGGGCT GGGAGGGGG GGAGGCTTGT AAGTGCCAGG CTAGACTGCA	2378
10	GATGAACTCC CCTGGCCTGC CTCTCTCAAC TGTGTATGTA CATATATATT TTTTTTAAT	2438
	TTGATGAAAG CTGATTACTG TCAATAAAACA GCTTCCTGCC TTTGTAAGTT ATTCCATGTT	2498
	TGTTGTTTG GGTGTCCCTGC CCAGTGTGGT TAAATAAGAG ATTTGAAGCA TTCTGAGTTT	2558
15	ACCATTGTA ATAAAGTATA TAATTTTTT ATGTTTGTGTT TCTGAAAATT TCCAGAAAAGG	2618
	ATATTAAAGA AAATAACAATA AACTATTGAA AAGTAGCCCC CAACCTCTT GCTGCATTAT	2678
	CCATAGATAA TGATAGCTAG ATGAAGTGAC AGCTGAGTGC CCCCAATATA CTAGGGTGAA	2738
20	AGCTGTGTCC CCTGTCTGAT TTGTAGGAAT AGATACCCCTG CATGCTATCA TTGGCTCAT	2798
	CTCTCTCCCC CGGCAACACCA CAAGTCCAGA CTGTACACCA GAAGATGGTG TGGTGTCT	2858
	TAAGGCTGGA AGAAGGGCTG TTGCAAGGGG AGAGGGTCAG CCCGCTGGAA AGCAGACACT	2918
25	TTGGTTGAAA GCTGTATGAA GTGGCATGTG CTGTGATCAT TTATAATCAT AGGAAAGATT	2978
	TAGTAATTAG CTGTTGATTC TCAAAGCAGG GACCCATGGA ACTTTTTAAC AAAAGGTGTC	3038
	TCCTTCCAAC TTTGAATCTG ACAACTCCTA GAAAAAGATG ACCTTGCTT GTGCATATTT	3098
	ATAATAGCGT TCGTTATCAC AATAATGTA TTCAAT	3135

25

(2) INFORMATION FOR SEQ ID NO:2:

30	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 334 amino acids
	(B) TYPE: amino acid
	(D) TOPOLOGY: linear
35	(ii) MOLECULE TYPE: protein
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
	Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp Asp Ala Leu Asn Ala
	1 5 10 15
	Ser Phe Leu Gln Ser Glu Ser Gly Ala Tyr Gly Tyr Ser Asn Pro Lys
	20 25 30
45	Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala Asp Pro Val Gly Ser
	35 40 45
	Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp Leu Leu Thr Ser Pro
	50 55 60
55	Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu Leu Glu Arg Leu Ile
	65 70 75 80
	Ile Gln Ser Ser Asn Gly His Ile Thr Thr Pro Thr Pro Thr Gln
	85 90 95
60	Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln Glu Gly Phe Ala Glu
	100 105 110

55

Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser Gln Asn Thr Leu Pro
 115 120 125
 5 Ser Val Thr Ser Ala Ala Gln Pro Val Ser Gly Ala Gly Met Val Ala
 130 135 140
 Pro Ala Val Ala Ser Val Ala Gly Ala Gly Gly Gly Gly Tyr Ser
 145 150 155 160
 Ala Ser Leu His Ser Gln Glu Pro Pro Val Tyr Ala Asn Leu Ser Asn Phe
 10 165 170 175
 Asn Pro Gly Ala Leu Ser Ser Gly Gly Ala Pro Ser Tyr Gly Ala
 180 185 190
 15 Ala Gly Leu Ala Phe Pro Ser Gln Pro Gln Gln Gln Gln Pro Pro
 195 200 205
 Gln Pro Pro His His Leu Pro Gln Gln Ile Pro Val Gln His Pro Arg
 210 215 220
 Leu Gln Ala Leu Lys Glu Glu Pro Gln Thr Val Pro Glu Met Pro Gly
 225 230 235 240
 20 Glu Thr Pro Pro Leu Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile
 245 250 255
 Lys Ala Glu Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys
 260 265 270
 25 Arg Lys Arg Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys
 275 280 285
 Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu
 290 295 300
 30 Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Asn
 305 310 315 320
 Ser Gly Cys Gln Leu Met Leu Thr Gln Gln Leu Gln Thr Phe
 325 330
 35

(2) INFORMATION FOR SEQ ID NO:3:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3622 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: cDNA

50 (ix) FEATURE:
 (A) NAME/KEY: mRNA
 (B) LOCATION: 287..3622

(ix) FEATURE:
 (A) NAME/KEY: mRNA
 (B) LOCATION: 289..3622

(ix) FEATURE:
 (A) NAME/KEY: mRNA
 (B) LOCATION: 293..3622

5 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1261..2256

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

10	CCCGGGGAGG GGACCGGGGA ACAGAGGGCC GAGAGCCGTG CGGCAGGGGG GAGGGTAGGA	60
	GAAAGAAGGG CCCGACTGTA GGAGGGCAGC GGAGCATTAC CTCATCCCGT GAGCCTCCGC	120
	GGGCCAGAG AAGAATCTTC TAGGGTGGAG TCTCCATGGT GACGGCGGG CCCGCCCCC	180
15	TGAGAGCCAC CGCAGCCAAT CGGAAGGCCT TGGGGTGACA TCATGGGCTA TTTTAGGGG	240
	TTGACTGGTA CGCAGATAAGT GTTGAGCTCG GGCTGGATAA GGCTCAGAG TTGCACTGAG	300
	TCTGGCTGAA CCAGGGAGGC CGGAGTGGAG GTGCCGGAG TCAGGCAGAC AGACAGACAC	360
20	AGCCAGCCAG CCAGGTCGGC AGTATAGTCC GAACTGCAA TCTTATTTTC TTTTCACCTT	420
	CTCTCTAACT GCCCAGAGCT AGCGCCTGTG GCTCCGGGC TGGTGGTTCG GGAGTGTCCA	480
	GAGAGCCTTG TCTCCAGCCG GCCCCGGGAG GAGAGCCTG CTGCCAGGC GCTGTTGACA	540
25	CGGGCGGAAA CGAGCGGTAC CCCACGGGCC CGCCGGGGGA CGTCGGCGAG CGGCTGCAGC	600
	AGCAAAGAAC TTTCCGGCG GGGAGGACCG GAGACAAGTG GCAGAGTCCC GGAGCGAACT	660
	TTTGCAAGCC TTTCTGGGT CTTAGGCTTC TCCACGGCGG TAAAGACCAG AAGGCGGGCG	720
	AGACCCACCC AAGACAACAA GGACGTGGCC TCAGCTTCGG TCGCACCGGT TGTGAACTT	780
30	GGGGCAGCCG GAGCCGGGGC TGCCGGGGC CCCCTCCCCC TAGCAGGGGA GGAGGGGACA	840
	AGTCGTGGG GTCCGGGGCGG CCAAGACCCG CGCCGGGGCG GCCACTGCAG GGTCCGCAGT	900
	GATCCGCTCC CGGGGGAGAG CGCCTGCTCT GGGAAAGTGAG TTCCGCTGCG GACTCCGAGG	960
35	AACCGCTGCG CCCGAAGAGC GCTCAGTGAG TGACCCGAC TTTCAAAGC CGGGTAGGCC	1020
	CGGGGAGTCG ACAAATAAGA GTGGGGAGG CATCTTAATT AACCTGGCG TCCCTGGAGC	1080
	GAGCTGGTGA GGAGGGCGCA CGGGGGACGA CAGCCAGGG GTGGGTGGCG TCTTAGAGAA	1140
40	ACTTCCCTG TCAAAGGCTC CGGGGGGGCGC GGGTGTCCCC CGCTTGCCAG AGCCCTGTTG	1200
	CGGCCCCGAA ACTTGTGGCGC GCACGCCAAA CTAACCTCAC GTGAAGTGAC GGACTGTTCT	1260
	ATG ACT GCA AAG ATG GAA ACG ACC TTC TAT GAC GAT GCC CTC AAC GCC Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp Asp Ala Leu Asn Ala	1308
	1 5 10 15	
45	TCG TTC CTC CCG TCC GAG AGC GGA CCT TAT GGC TAC AGT AAC CCC AAG Ser Phe Leu Pro Ser Glu Ser Gly Pro Tyr Gly Tyr Ser Asn Pro Lys	1356
	20 25 30	
50	ATC CTG AAA CAG AGC ATG ACC CTG AAC CTG GCC GAC CCA GTG GGG AGC Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala Asp Pro Val Gly Ser	1404
	35 40 45	

	CTG AAG CCG CAC CTC CCC GCC AAG AAC TCG GAC CTC CTC ACC TCG CCC Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp Leu Leu Thr Ser Pro 50 55 60	1452
5	GAC GTG GGG CTG CTC AAG CTG GCG TCG CCC GAG CTG GAG CGC CTG ATA Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu Leu Glu Arg Leu Ile 65 70 75 80	1500
10	ATC CAG TCC ACC AAC GGG CAC ATC ACC ACC ACG CCC ACC CCC ACC CAG Ile Gln Ser Ser Asn Gly His Ile Thr Thr Thr Pro Thr Pro Thr Gln 85 90 95	1548
	TTC CTG TGC CCC AAG AAC GTG ACA GAT GAG CAG GAG GGG TTC GCC GAG Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln Glu Gly Phe Ala Glu 100 105 110	1596
15	GCC TTC GTG CGC GCC CTG GCC GAA CTG CAC AGC CAG AAC ACG CTG CCC Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser Gln Asn Thr Leu Pro 115 120 125	1644
20	AGC GTC ACG TCG GCG GCG CAG CCG GTC AAC GGG GCA GGC ATG GTG CCT Ser Val Thr Ser Ala Ala Gln Pro Val Asn Gly Ala Gly Met Val Ala 130 135 140	1692
	CCC GCG GTC GCC TCG GTG GCA GGG GGC AGC GGC AGC GGC GGC TTC AGC Pro Ala Val Ala Ser Val Ala Gly Gly Ser Gly Gly Phe Ser 145 150 155 160	1740
25	GCC AGC CTG CAC AGC GAG CCG CCG GTC TAC GCA AAC CTC AGC AAC TTC Ala Ser Leu His Ser Glu Pro Pro Val Tyr Ala Asn Leu Ser Asn Phe 165 170 175	1788
	AAC CCA GGC GCG CTG AGC AGC GGC GGC GGG GCG CCC TCC TAC GGC GCG Asn Pro Gly Ala Leu Ser Ser Gly Gly Ala Pro Ser Tyr Gly Ala 180 185 190	1836
30	GCC GGC CTG GCC TTT CCC GCG CAA CCC CAG CAG CAG CAG CAG CCG CCG Ala Gly Leu Ala Phe Pro Ala Gln Pro Gln Gln Gln Gln Pro Pro 195 200 205	1884
35	CAC CAC CTG CCC CAG CAG ATG CCC GTG CAG CAC CCG CGG CTG CAG GCC His His Leu Pro Gln Gln Met Pro Val Gln His Pro Arg Leu Gln Ala 210 215 220	1932
	CTG AAG GAG GAG CCT CAG ACA GTG CCC GAG ATG CCC GGC GAG ACA CCG Leu Lys Glu Glu Pro Gln Thr Val Pro Glu Met Pro Gly Glu Thr Pro 225 230 235 240	1980
40	CCC CTG TCC CCC ATC GAC ATG GAG TCC CAG GAG CGG ATC AAG GCG GAG Pro Leu Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile Lys Ala Glu 245 250 255	2028
45	AGG AAG CGC ATG AGG AAC CGC ATC GCT GCC TCC AAG TGC CGA AAA AGG Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys Arg Lys Arg 260 265 270	2076
	AAG CTG GAG AGA ATC GCC CGG CTG GAG GAA AAA GTG AAA ACC TTG AAA Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys 275 280 285	2124
50	GCT CAG AAC TCG GAG CTG GCG TCC ACG GCC AAC ATG CTC AGG GAA CAG Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Gln 290 295 300	2172

EP 0 599 077 A2

GTG GCA CAG CTT AAA CAG AAA GTC ATG AAC CAC GTT AAC AGT CGG TGC Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Asn Ser Gly Cys 305 310 315 320	2220
5 CAA CTC ATG CTA ACG CAG CAG TTG CAA ACA TTT TGAAGAGAGA CCGTCGGGG Gln Leu Met Leu Thr Gln Gln Leu Gln Thr Phe 325 330	2273
10 CTCAGGGCA ACGAAGAAAA AAAATAACAC AGAGAGACAG ACTTGAGAAC TTGACAAGTT	2333
15 GCGACGGAGA GAAAAAAAGAA GTGTCCGAGA ACTAAAGCCA AGGGTATCCA ACTTGGACTG GGTTCCGTCT GACGGCGCCC CCAGTGTGCA CGAGTGGAA GGACTTGGTC GCGCCCTCCC TTGGCGTGGA GCCAGGGAGC GCGCCGCTGC GGGCTCCCC GCTTGGGA CGGGCTGTCC CCGCAGGAAC GGAACGTTGG ACTTTCGTTA ACATTGACCA AGAACTGCAT GGACCTAAC TTCGATCTCA TTCACTTAAAGGGGGAG CGGGAGGGGG TTACAAACTG CAATAGAGAC TGTAGATTGC TTCTGTAGTA CTCCCTAAGA ACACAAAGCG CGGGGAGGGT TGGGGAGGG CGGCAGGGAGG GAGGTTGTG AGAGCAGGC TGAGCCTACA GATGAACTCT TTCTGGCCTG 20 CTTTCGTTAA CTGTGTATGT ACATATATAT ATTTTTAAAT TTGATTAAG CTGATTACTG	2573
25 TCAATAAACCA GCTTCATGCC TTTGTAAGTT ATTTCTTGTG TGTTTGTGTT GGTATCCTGC CCAGTGTGTG TTGTAATAAAG GAGATTTGGA GCACTCTGAG TTTACCATTT GTAATAAAAGT ATATAATTTT TTATGTTTT GTTCTGAAA ATTCCAGAAA GGATATTTAA GAAATACAA	2633
30 TAAACTATTG GAAAGTACTC CCCTAACCTC TTTCTGCAT CATCTGTAGA TCCTAGTCTA TCTAGGTGGA GTTGAAGAG TTAAGAATGC TCGATAAAAT CACTCTCAGT GCTTCTTACT ATTAAGCAGT AAAAATCTTT CTCTATTAGA CTTAGAAATA AATGTACCTG ATGTACCTGA TGCTATGTCA GGCTTCATAC TCCACGCTCC CCCAGCGTAT CTATATGGAA TTGCTTACCA	2993
35 AAGGCTAGTG CGATGTTCA GGAGGCTGGA GGAAGGGGG TTGAGTGGGA GAGGGACAGC CCACTCAGAA GTCAAAACATT TCAAAGTTTG GATTGCATCA AGTGGCATGT GCTGTGACCA TTTATAATGT TAGAAATTTT ACAATAGGTG CTTATTCTCA AAGCAGGAAT TGGTGGCAGA	3113
40 AGATGGCCTT TGTCTTATGA ATATTTATAA CAGCATTCTG TCACAATAAA TGTATTCAAA TACCAATAAC AGATCTTGAA TTGCTTCCCT TTACTACTTT TTTGTTCCCA AGTTATAC TGAAGTTTTT ATTTTAGTT GCTGAGGTT	3413
45 (2) INFORMATION FOR SEQ ID NO:4:	3473
50 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 331 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: protein	3533
55	3593
	3622

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp Asp Ala Leu Asn Ala
 1 5 10 15

5 Ser Phe Leu Pro Ser Glu Ser Gly Pro Tyr Gly Tyr Ser Asn Pro Lys
 20 25 30

Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala Asp Pro Val Gly Ser
 35 40 45

10 Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp Leu Leu Thr Ser Pro
 50 55 60

Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu Leu Glu Arg Leu Ile
 65 70 75 80

15 Ile Gln Ser Ser Asn Gly His Ile Thr Thr Pro Thr Pro Thr Gln
 85 90 95

Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln Glu Gly Phe Ala Glu
 100 105 110

20 Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser Gln Asn Thr Leu Pro
 115 120 125

Ser Val Thr Ser Ala Ala Gln Pro Val Asn Gly Ala Gly Met Val Ala
 130 135 140

25 Pro Ala Val Ala Ser Val Ala Gly Gly Ser Gly Ser Gly Phe Ser
 145 150 155 160

Ala Ser Leu His Ser Glu Pro Pro Val Tyr Ala Asn Leu Ser Asn Phe
 165 170 175

30 Asn Pro Gly Ala Leu Ser Ser Gly Gly Ala Pro Ser Tyr Gly Ala
 180 185 190

Ala Gly Leu Ala Phe Pro Ala Gln Pro Gln Gln Gln Gln Pro Pro
 195 200 205

His His Leu Pro Gln Gln Met Pro Val Gln His Pro Arg Leu Gln Ala
 210 215 220

35 Leu Lys Glu Glu Pro Gln Thr Val Pro Glu Met Pro Gly Glu Thr Pro
 225 230 235 240

Pro Leu Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile Lys Ala Glu
 245 250 255

40 Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys Arg Lys Arg
 260 265 270

Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys
 275 280 285

45 Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Gln
 290 295 300

Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Asn Ser Gly Cys
 305 310 315 320

50 Gln Leu Met Leu Thr Gln Gln Leu Gln Thr Phe
 325 330

(2) INFORMATION FOR SEQ ID NO:5:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3548 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ix) FEATURE:
 (A) NAME/KEY: TATA_signal
 (B) LOCATION: 101..106

15 (ix) FEATURE:
 (A) NAME/KEY: polyA signal
 (B) LOCATION: 3493..3498

20 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 284..424

25 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 1179..1430

30 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 1836..1943

35 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 2061..2702

40 (ix) FEATURE:
 (A) NAME/KEY: precursor_RNA
 (B) LOCATION: 133..2702

45 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 425..1178

50 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 1431..1835

55 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 1944..2060

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAGTTGACGA	CAGAGCGCCC	GCAGAGGGCC	TTGGGGCGCG	CTTCCCCCCC	CTTCCAGTTC	60
CGCCCACTGA	CGTAGGAAGT	CCATCCATTC	ACAGCGCTTC	TATAAAGGCG	CCAGCTGAGG	120
45 CGCCTACTAC	TCCAACCGCG	ACTGCAGCGA	GCAACTGAGA	AGACTGGATA	GAGCCGGCGG	180
TTCCGCGAAC	GAGCAGTGAC	CGCGCTCCCA	CCCAGCTCTG	CTCTGCAGCT	CCCACCCAGTG	240
TCTACCCCTG	GACCCCTTGC	CGGGCTTTCC	CCARACTTCG	ACCATGATGT	TCTCGGGTTT	300
50 CAACGCCGAC	TACGAGGCCGT	CATCCTCCCG	CTGCAGTAGC	GCCTCCCCGG	CCGGGGACAG	360
CCTTCCTAC	TACCATTCCC	CAGCCGACTC	CTTCTCCAGC	ATGGGCTCTC	CTGTCAACAC	420

	ACAGGTGAGT TTGGCTTTGT GTAGCCGCCA GGTCCCGCCT GAGGGTCGCC GTGGAGGAGA	480
5	CACTGGGTG TGACTCCAG GGGCGGGGG GTCTTCCTT TTGCTCTGG AGGGAGACTG	540
	GCGCGCTAG AGCAGCCTTA GCCTGGAAAC CCAGGACTTG TCTGAGGCCG TGACACTTG	600
	TCATAGTAAG ACTTACTGAC CCCTTCCCGC GCGGCAGGTT TATTCTGAGT GGCCCTGCCCTG	660
	CATTCTCTC TCGGCCGACT TGTTCTGAG ATCAGCCGGG GCCAACAAAGT CTGGAGCAAA	720
10	GAGTCGCTAA CTAGAGTTG GGAGGGCGCA AACCCCGGCA ATCCCCCCTC CCGGGGCAGC	780
	CTGGAGCAGG GAGGAGGGAG GAGGGAGGAG GGTGCTGCCG GCGGGTGTGT AAGGCAGTTT	840
	CATTGATAAA AAGCGAGTTC ATTCTGGAGA CTCCCGACCA GCGCCTGCCGT CAGCGCAGAC	900
15	GTCAGGGATA TTTATAACAA ACCCCCTTC GAGCGAGTGA TGCCGAAGGG ATAACGGAA	960
	CGCAGCAGTA GGATGGAGGA GAAAGGCTGC GCTGCGGAAT TCAAGGGAGG ATATTGGGAG	1020
	AGCTTTTATC TCCGATGAGG TGCATACAGG AAGACATAG CAGTCCTGTA CGCGAATGCT	1080
	TCTCTCTCCC TGCTTCATGC GACACTAGGG CCACTTGCTC CACCTGTGTC TGGAACCTCC	1140
20	TCGCTCACCT CCGCTTCCCT CTTTTCTTT TGTTCAAGGA CTTTGCAGCA GATCTGTCCG	1200
	TCTCTAGTGC CAACTTTATC CCCACGGTGA CAGCCATCTC CACCAGCCCA GACCTGCAGT	1260
	GGCTGGTGCA GCCCCTCTG GTCTCCTCCG TGGCCCCATC GCAGACCAGA GCGCCCCATC	1320
25	CTTACGGACT CCCCACCCAG TCTGCTGGGG CTTACGCCAG AGCGGGAAATG GTGAAGACCG	1380
	TGTCAGGAGG CAGACCGCAG AGCATCGCA GAAGGGCAA AGTAGAGCAG GTGAGCAGCG	1440
	ATTCTGGACC TTTGTGGGCT GGGGGGGGG GGGGGGGGG AGACTGACCC ACAGACCACAA	1500
30	CAACAGAGAA GGGACGCTAC TGACTGCACT TCCTGACCAAG GAGCTGTGGC TGCTAGCCCT	1560
	TTCCCTCCCT TGTCAGATT TGACAGTTGG ACCCAAGACA AACTCTAGAC AGTTTCCCTG	1620
	ACAGCTTCCCT ACTTCATTCT CTAGCCCCGG AGCTTCTTG TTCCCTGCT AAAGATCTCA	1680
	CTTTAAATGCA AAATCACACT CTGCGCTGCCA ACTGCAGGTT AGAAAAAACTG CTTCACCGAG	1740
35	AGGTGCGGGT GCTGTAGGAG CCAGTTTCAC TGGGGTCACT GAATGGAGGT GACACTAGAC	1800
	AACCTTAACT GAATGTTGGT CCTTTCTTC TATAGCTATC TCCTGAAGAG GAAGAGAAAC	1860
	GGAGAATCCG AAGGGAACGG AATAAGATGG CTGCAGCCAA GTGCCGGAAAT CGGAGGAGGG	1920
40	AGCTGACAGA TACACTCCAA GCGGTAGGTT GAACCAAGCTG CTGCTCCCTGA AACTTTATTA	1980
	AAGTTGGAGC TTGGGACTAT GGGCGCAGGG TCCTTGAGCA TGCCCGTGTGTC TTATGCTTTC	2040
	TTATATCTCT CCCTATGCAG GAGACAGATC AACTTGAAAGA TGAGAAGTCT GCGTTGCAGA	2100
45	CTGAGATTGC CAATCTGCTG AAAGAGAAGG AAAAAGTGGG GTTTATTTG GCAGCCCACC	2160
	GACCTGCCTG CAAGATCCCC GATGACCTTG GCTTCCCGAGA GGAGATGTCT GTGGCCTCCC	2220
	TGGAGTTGAC TGGAGGTCTG CCTGAGGCTT CCACCCCGAGA GTCTGAGGAG GCCTTCACCC	2280
50	TGCCCCCTCT CAACGACCCCT GAGCCCAAGC CATCCTTGGA GCCAGTCAG AGCATCAGCA	2340
	ACGTGGAGCT GAAGGCAGAA CCCTTGTGATG ACTTCTTGTG TCCGGCATCA TCTAGGCCCCA	2400

	GTGGCTCAGA GACCTCCCGC TCTGTGCCAG ATGTGGACCT GTCCGGTTCC TTCTATGCAG	2460
	CAGACTGGGA GCCTCTGCAC AGCAATTCTT TGGGGATGGG GCCCATGGTC ACAGAGCTGG	2520
5	AGCCCTGTG TACTCCCGTG GTCACTGTG CTCCGGCTG CACTACTTAC ACGTCTTCTT	2580
	TTGTCTTCAC CTACCCCTGAA GCTGACTCCT TCCCAAGCTG TGCCGCTGCC CACCGAAAGG	2640
	GCAGCAGCAG CAACGAGCCC TCCTCCGACT CCCTGAGCTC ACCCACGCTG CTGGCCCTGT	2700
10	GAGCAGTCAG AGAAGGCAAG GCAGCCGGCA TCCAGACGTG CCACTGCCCC AGCTGGTGCA	2760
	TTACAGAGAG GAGAAACACG TCTTCCCTCG AAGGTTCCCG TCGACCTAGG GAGGACCTTA	2820
	CCTGTTCTG AAACACACCA GGCTGTGGGC CTCAAGGACT TGCAAGGCATC CACATCTGGC	2880
15	CTCCAGTCCT CACCTCTTCC AGAGATGTAG CAAAAACAAA ACAAAACAAA ACAAAAAACC	2940
	GCATGGAGTG TGTGTTCCCT AGTGACACCT GAGAGCTGGT AGTTAGTGA GCATGTGAGT	3000
	CAAGGCTGG TCTGTGTCTC TTTTCTCTTT CTCCCTAGTT TTCTCATAGC ACTAACTAAT	3060
	CTGTTGGTT CATTATTGGA ATTAACCTGG TGCTGGATTG TATCTAGTGC AGCTGATTTT	3120
20	AACAATACCT ACTGTGTTC TGGCAATAGC GTGTTCCAAT TAGAAACGAC CAATATTAAT	3180
	CTAAGAAAAG ATAGGACTTT ATTTTCCAGT AGATAGAAAT CAATAGCTAT ATCCATGTAC	3240
	TGTACTCCTT CAGCGTCAAT GTTCATTGTC ATGTTACTGA TCATGCATTG TCGAGGTTGGT	3300
25	CTGAATGTTG TGACATTAAC AGTTTTCCAT GAAAACGTTT TTATTTGTTT TTCAATTAT	3360
	TTATTAAGAT GGATTCTCAG ATATTTATAT TTTTATTATA TTTTTTTCTA CCCTGAGGTC	3420
	TTTCGACATG TGGAAAGTGA ATTTGAATGA AAAATTTAA GCATTGTTG CTTATTGTT	3480
30	CAGGACATTG TCAATAAAAG CATTAAAGTT GAATGCCACC ACCTTCTTGC TCTCTTTATT	3540
	CTCAGTTT	3548

35 (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6210 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: join(889..1029, 1783..2034, 2466..2573, 2688..3329)
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 402..453
 - (D) OTHER INFORMATION: /note= "transcriptional activator region"

(ix) FEATURE:
 (A) NAME/KEY: prim transcript
 (B) LOCATION: 734..3329
 5 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 889..1029
 (D) OTHER INFORMATION: /note= "c-fos protein, exon1"
 10 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 1030..1782
 (D) OTHER INFORMATION: /note= "c-fos, intron A"
 15 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 1783..2034
 20 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 2035..2465
 25 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 2466..2573
 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 2574..2687
 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 2688..3329

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
 GCAGGAACAG TGCTAGTATT GCTCGAGCCC GAGGGCTGGA GGTTAGGGGA TGAAGGTCTG 60
 CTTCCACGCT TTGCACTGAA TTAGGGCTAG AATTGGGGAT GGGGGTAGGG GCGCATTCCCT 120
 TCGGGAGCCC AGGCTTAAGT CCTCGGGGTC CTGTACTCGA TGCCGTTCT CCTATCTCTG 180
 35 AGCCTCAGAA CTGTCTTCAG TTTCCGTACA AGGGTAAAAA GGCGCTCTCT GCCCCATCCC 240
 CCCCCGACCTC GGGAAACAAGG GTCCGCATTG AACCGAGTGC GAATGTTCTC TCTCATTCTG 300
 CGCCGTTCCC GCCTCCCCCTC CCCCAGCCGC GGCCCCCGCC TCCCCCCGCA CTGCACCCCTC 360
 40 GGTGTTGGCT GCAGCCCCGG AGCAGTTCCC GTCAATCCCT CCCCCCTTAC ACAGGATGTC 420
 CATATTAGGA CATCTGCGTC ACCAGGTTTC CACGGCCTTT CCCTGTAGCC CTGGGGGGAG 480
 CCATCCCCGA AACCCCTCAT CTTGGGGGGC CCACGAGACC TCTGAGACAG GAACTCCGAA 540
 45 ATGCTCACGA GATTAGGACA CGCGCCAAGG CGGGGGCAGG GAGCTGCCAG CGCTGGGAC 600
 GCAGCCGGGC GGCCGCAGAA GCGCCCAAGGC CCGCGCGCCA CCCCTCTGGC GCCACCGTGG 660
 TTGAGCCCCGT GACGTTTACA CTCATTCTATA AAACGCTTGT TATAAAAGCA GTGGCTGCGG 720
 50 CGCCTCGTAC TCCAACCGCA TCTGCAGCGA GCAACTGAGA AGCCAAGACT GAGCCGGCGG 780
 CCGCGGCGCA GCGAACGAGC AGTGACCGTG CTCCTACCCA GCTCTGCTTC ACAGCGCCCA 840

	CCTGTCTCCG CCCCTCGGCC CCTCGCCGG CTTGCCTAA CCGCCACG ATG ATG TTC Met Met Phe 1	897
5	TCG GGC TTC AAC GCA GAC TAC GAG GCG TCA TCC TCC CGC TGC AGC AGC Ser Gly Phe Asn Ala Asp Tyr Glu Ala Ser Ser Ser Arg Cys Ser Ser 5 10 15	945
	GCG TCC CCG GCC GGG GAT AGC CTC TCT TAC TAC CAC TCA CCC GCA GAC Ala Ser Pro Ala Gly Asp Ser Leu Ser Tyr Tyr His Ser Pro Ala Asp 20 25 30 35	993
10	TCC TTC TCC AGC ATG GGC TCG CCT GTC AAC GCG CAG GTAGGCTGG Ser Phe Ser Ser Met Gly Ser Pro Val Asn Ala Gln 40 45	1039
	CTTCCCGTCG CGCGGGGGCC GGGGGCTTGG GTGCGGGAG GAGGAGACAC CGGGCGGGAC GCTCCAGTAG ATGAGTAGGG GGCTCCCTTG TGCGTGGAGG GAGGCTGCCG TGGCCGGAGC GGTGGCGGCT CGGGGGCTCG GGACTTGCTC TGAGCGCACG CACCGTTGCC ATAGTAAGAA TTGGTTCCCC CTTGGGGAGG CAGGTTCGTT CTGAGCAACC TCTGGTCTGC ACTCCAGGAC 20 25 30 35	1099 1159 1219 1279
	GGATCTCTGA CATTAGCTGG ACCAGACGTG TCCCAAGCAC AAACCTCGCTA ACTAGAGCCT GGCTTCTTCG GGGAGGTGGC AGAAAGCGC AATCCCCCT CCCCCGGCAG CCTGGAGCAC GGAGGGAGGA TGAGGGAGGA GGGTGCAGCG GGCGGGTGTG TAAGGCAGTT TCATTGATAA AAAGCGAGTT CATTCTGGAG ACTCCGGAGC GGCGCCTGCG TCAGCGCAGA CGTCAGGGAT 25 30 35	1339 1399 1459 1519
	ATTTATAACA AACCCCCCTTT CAAGCAACTG ATGCTGAAGG GATAACGGGA ACGCAGCGGC AGGATGGAAG AGACAGGCAC TCGCGCTGGG AATGCCTGGG AGGAAAAGGG GGAGACCTTT CATCCAGGAT GAGGGACATT TAAGATGAAA TGTCCGTGGC AGGATCGTTT CTCTTCACTG 30 35	1579 1639 1699
	CTGCATGCGG CACTGGGAAC TCGCCCCACC TGTGTCCGG A CCTGCTCGC TCACGTCCGC TTTCCCCCTTC TGTTTGTTTC TAG GAC TTC TGC ACG GAC CTG GCC GTC TCC Asp Phe Cys Thr Asp Leu Ala Val Ser 50 55	1759 1809
	AGT GCC AAC TTC ATT CCC ACG GTC ACT GCC ATC TCG ACC AGT CCG GAC Ser Ala Asn Phe Ile Pro Thr Val Thr Ala Ile Ser Thr Ser Pro Asp 60 65 70	1857
	CTG CAG TGG CTG GTG CAG CCC GCC CTC GTC TCC TCT GTG GCC CCA TCG Leu Gln Trp Leu Val Gln Pro Ala Leu Val Ser Ser Val Ala Pro Ser 75 80 85	1905
40	CAG ACC AGA GCC CCT CAC CCT TTC GGA GTC CCC GCC CCC TCC GCT GGG Gln Thr Arg Ala Pro His Pro Phe Gly Val Pro Ala Pro Ser Ala Gly 90 95 100	1953
	GCT TAC TCC AGG GCT GGC GTT GTG AAG ACC ATG ACA GGA GGC CGA GCG Ala Tyr Ser Arg Ala Gly Val Val Lys Thr Met Thr Gly Gly Arg Ala 105 110 115 120	2001
45	CAG AGC ATT GGC AGG AGG GGC AAG GTG GAA CAG GTGAGGAAC TCTAGCGTACT Gln Ser Ile Gly Arg Arg Gly Lys Val Glu Gln 125 130	2054
50	CTTCCTGGGA ATGTGGGGGC TGGGTGGGAA GCAGCCCCGG AGATGCAGGA GCCCACTACA	2114

	GAGGATGAAG CCACTGATGG GGCTGGCTGC ACATCCGTAA CTGGGAGCCC TGGCTCCAAG	2174
5	CCCATTCCAT CCCAACTCAG ACTCTGAGTC TCACCCCTAAG AAGTACTCTC ATAGTTTCTT	2234
	CCCTAAGTTT CTTACCGCAT GCTTCAGAC TGGGCTCTTC TTGTTCTCT TGCTGAGGAT	2294
	CTTATTTAA ATGCAAGTCA CACCTATTCT GCAACTGCAG GTCAGAAATG GTTTCACAGT	2354
	GGGGTGCAG AGCTGCAGGA GCCAGTTCTA CTGGGGTGGG TGAATGGAGG	2414
10	TGATGGCAGA CACTTTACT GAATGTCGGT CTTTTTTGT GATTATTCTA G TTA TCT Leu Ser	2471
	CCA GAA GAA GAA GAG AAA AGG AGA ATC CGA AGG GAA AGG AAT AAG ATG Pro Glu Glu Glu Glu Lys Arg Arg Ile Arg Arg Glu Arg Asn Lys Met 135 140 145	2519
15	GCT GCA GCC AAA TGC CGC AAC CGG AGG AGG GAG CTG ACT GAT ACA CTC Ala Ala Ala Lys Cys Arg Asn Arg Arg Arg Glu Leu Thr Asp Thr Leu 150 155 160 165	2567
	CAA GCG GTAGGTACTC TGTGGGTTGC TCCCTTTAA AACTTAAGGG AAAGTTGGAG Gln Ala	2623
20	ATTGAGCATA AGGGCCCTTG AGTAAGACTG TGTCTTATGC TTTCTTTAT CCCTCTGTAT	2683
	ACAG GAG ACA GAC CAA CTA GAA GAT GAG AAG TCT GCT TTG CAG ACC GAG Glu Thr Asp Gln Leu Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu 170 175 180	2732
25	ATT GCC AAC CTG CTG AAG GAG AAG GAA AAA CTA GAG TTC ATC CTG GCA Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala 185 190 195	2780
	GCT CAC CGA CCT GCC TGC AAG ATC CCT GAT GAC CTG CCC TTC CCA GAA Ala His Arg Pro Ala Cys Lys Ile Pro Asp Asp Leu Gly Phe Pro Glu 200 205 210	2828
30	GAG ATG TCT GTG GCT TCC CTT GAT CTG ACT GGG GGC CTG CCA GAG GTT Glu Met Ser Val Ala Ser Leu Asp Leu Thr Gly Gly Leu Pro Glu Val 215 220 225 230	2876
	GCC ACC CCG GAG TCT GAG GAG GCC TTC ACC CTG CCT CTC CTC AAT GAC Ala Thr Pro Glu Ser Glu Ala Phe Thr Leu Pro Leu Leu Asn Asp 235 240 245	2924
35	CCT GAG CCC AAG CCC TCA GTG GAA CCT GTC AAG AGC ATC AGC AGC ATG Pro Glu Pro Lys Pro Ser Val Glu Pro Val Lys Ser Ile Ser Ser Met 250 255 260	2972
40	GAG CTG AAG ACC GAG CCC TTT GAT GAC TTC CTG TTC CCA GCA TCA TCC Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe Leu Phe Pro Ala Ser Ser 265 270 275	3020
	AGG CCC AGT GGC TCT GAG ACA GCA GCC CGC TCC GTG CCA GAC ATG GAC CTA Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser Val Pro Asp Met Asp Leu 280 285 290	3068
45	TCT GGG TCC TTC TAT GCA GCA GAC TGG GAG CCT CTG CAC AGT GGC TCC Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu Pro Leu His Ser Gly Ser 295 300 305 310	3116
50	CTG GGG ATG GGG CCC ATG GCC ACA GAG CTG GAG CCC CTG TGC ACT CCG Leu Gly Met Gly Pro Met Ala Thr Glu Leu Glu Pro Leu Cys Thr Pro 315 320 325	3164

	GTG GTC ACC TGT ACT CCC AGC TGC ACT GCT TAC ACG TCT TCC TTC GTC Val Val Thr Cys Thr Pro Ser Cys Thr Ala Tyr Thr Ser Ser Phe Val 330 335 340	3212
5	TTC ACC TAC CCC GAG GCT GAC TCC TTC CCC AGC TGT GCA GCT GCC CAC Phe Thr Tyr Pro Glu Ala Asp Ser Phe Pro Ser Cys Ala Ala Ala His 345 350 355	3260
10	CGC AAG GGC AGC AGC AAT GAG CCT TCC TCT GAC TCG CTC AGC TCA Arg Lys Gly Ser Ser Ser Asn Glu Pro Ser Ser Asp Ser Leu Ser Ser 360 365 370	3308
15	CCC ACG CTG CTG GCC CTG TGAGGGGGCA GGGAAAGGGGA GGCAGCCGGC Pro Thr Leu Leu Ala Leu 375 380	3356
20	ACCCACAAGT GCCACTGCCG GAGCTGGTGC ATTACAGAGA GGAGAAACAC ATCTTCCCTA GAGGGTTCT GTAGACCTAG GGAGGACCTT ATCTGTGCGT GAAACACACC AGGCTGTGG CCTCAAGGAC TTGAAAGCAT CCATGTGTGG ACTCAAGTCC TTACCTCTTC CGGAGATGTA GCAAAACCCA TCGAGTGTGT ATTGTTCCCA GTGACACTTC AGAGAGCTGG TAGTTAGTAG CATGTTGAGC CAGGCCCTGGG TCTGTGTCTC TTTTCTCTTT CTCTTAGTC TTCTCATAGC ATTAACATAAT CTATTGGTT CATTATTGGA ATTAACCTGG TGCTGGATAT TTTCAAATTG TATCTAGTGC AGCTGATTTT AACAATAACT ACTGTGTCC TGGCAATAGT GTGTTCTGAT TAGAAATGAC CAATATTATA CTAAGAAAAG ATACGACTTT ATTTTCTGGT AGATAGAAAT AAATAGCTAT ATCCATGTAC TGTAGTTTT CTTCAACATC AATGTTCAATT GAAATGTTAC TGATCATGCA TTGTTGAGGT GGTCTGAATG TTCTGACATT AACAGTTTC CATGAAAACG TTTTATTGTG TTTTAATT TTATTAAG ATGGATTCTC AGATATTAT ATTTTATT TATTTTTCTC TACCTTGAGG TCTTTGACA TGTGGAAAGT GAATTGAAAT GAAAATTAA AGCATTGTT CCTTATTGTT CCAAGACATT GTCAATAAAA GCATTTAAGT TGAATGCGAC CAACCTTGTC CTCTTTCTAT TCTGGAAAGTC TTGTAAGTTT CTGAAAGGTA TTATTGGAGA 35 CCAGTTGTC AACAGGGTA GCTGCTGGAG GGGGACACAC CCTCTGTCTG ATCCCTTATC AAAGAGGACA AGGAAACTAT AGAGCTGATT TTAGAATATT TTACAAATAC ATGCCCTCCA TTGGAATGCT AAGATTTCT ACTGCTTCTG GGGACGGGAA ACCGCTGTGT AACAGCTTTT 40 GTGGGAATAC ATTTTTCTG TTTCACTACT CGCAGGGGGA AATATTAAA TTTTGTGTG CTAATATTAA ATTCAAGATGT TTTGATCTTA AAGGAACCTT TTAAGCAAAC AGAACCTAGC TTTGTACAGA CTATTTAAC TTTTATTCT CACAAAATCA CGTGGAGGGT TATTCTACTT 45 CAAAGATGAG CAAATTGAAG AATGGTTAGA ATAAACAATC TTCTGTAT TCCGTTATCG GCATTAGAAT CTTCTGCTC GTTATCGTAT CCAGCAGGCT GAACTGCCCTC TTGATACTTG GTTAAAAAAA ATTTCAAGGC CGGGCGGGT GGGCCATGCC TGTAATCCTA GCACTTTGGG AGGCCGAGGC AGGCCGATCA CCTGAGGTGCG GGAGTTCGAG ACCAGCCTGA CCAACATGGA 50 GAAACCCCGT CTTTACTAAA AATACAAAAAT TACCTGGTG TGCTGGTCA TGCCTGTAAT	4496

5	CCTAGCTACT TGAGAGGCTG AGACAGGAAA ATCACCTGAA CTCGGGAGGC GGATGTTGCA	4916
	GCGAACTGAG ATTGCGCCAT TGCACCTCCAG CCTGGGCAAC AAAGATTGAAA CTCTGTTAA	4976
	AAAAAAAAGT TTTCACTAAT GTGTACATT TTTGTACTC TTTTATTCTC GAAAGGGAAAG	5036
10	GAGGGCTATT GCCCTATCCC TTATTAATAA ATGCATTGTG GTTTCTGGTT TCTCTAATAC	5096
	CATATGCCCT TCATTCAAGT TATAGTGGGC CGAAGTGGGG GAGAAAAAAGT TGCTCAGAAA	5156
	TCAAAAGATA TCTCAAAACAG CACAAATAAT GGCTGATCGT TCTGCAAACA AAAAGTTACA	5216
15	TAATAGCTCA AGAAGGAGAA GTCAACATGA CTCTGAACAA GCTTTAACCT AGAAACTTTA	5276
	TCATCTTAAG GAAGAACGTG ACCTTTGTCC AGGACGTCTC TGGTAATGGG GCACCTACAC	5336
	ACACATGCAC ACGTACAAAC CACAGGGAAA CGAGACCGCC CTTCTGCCTC TGCTCGGAG	5396
20	TATCACGCAG GCACCATGCA CTATGTTTC ACACACACTG GGTGGAAGAA GAGCTTCAGC	5456
	GCCAGTCTTC TAATGCTTTG GTGATAATGA AAATCACTGG GTGCTTATGG GGTGTCATAT	5516
	TCAATCGAGT TAAAAGTTT AATTCAAAAT GACAGTTTA CTGAGGTTGA TGTTCTCGTC	5576
25	TATGATATCT CTGCCCTCC CATAAAAATG GACATTTAAA AGCAACTTAC CGCTCTTAG	5636
	ATCACTCCTA TATCACACAC CACTTGGGGT GCTGTTCTG CTAGACTTGT GATGACAGTG	5696
	GCCTTAGGAT CCCTGTTGC TGTCAAAAGG GCAAATATTT TATAGCCTTT AAATATACCT	5756
30	AAACTAAATA CAGAATTAAT ATAACAAACA AACACCTGGT CTGAAATAAC AAGGTGATCT	5816
	ACCCCTGGAAG GAAACCCAGCT GGTGGGCCAG GAGCGGTGGC TCACACCTGT AATTCCAGCA	5876
	CTTTGGGAGG CTGAGACAGG AGGATCACTG GAGTCCAGGA GTTTGAGACC AGCCTGGCA	5936
35	ACATGGCAAA ACCCAGTGTG CTTCTGTTGT CCCAGCTACA CTACTCAGGA GGCTGAGGCA	5996
	GGAGTATGAC TTGAGCCTGG GAGGGGGAGG TTGAGAGAA CTGATATTGC ACCACCACTG	6056
	CACTCCAGCC TGGGTGACAC ACCAAAACCC TATCTCAAA AAAAAAAA AAAAAAGGAA	6116
	CCCAGCTGGT TCCCTGTAGGT GTGCAATAAT AACAAACCAGA GGAAGAAAAG GAAGACGATT	6176
40	TCCCAGATGAA AGAAGGGCAG CTGGACCTTC GGAC	6210

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 380 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met	Met	Phe	Ser	Gly	Phe	Aaa	Ala	Asp	Tyr	Glu	Ala	Ser	Ser	Ser	Arg
1					5					10					15

50	Cys	Ser	Ser	Ala	Ser	Pro	Ala	Gly	Asp	Ser	Leu	Ser	Tyr	Tyr	His	Ser
	20									25					30	

Pro Ala Asp Ser Phe Ser Ser Met Gly Ser Pro Val Asn Ala Gln Asp
 35 40 45
 Phe Cys Thr Asp Leu Ala Val Ser Ser Ala Asn Phe Ile Pro Thr Val
 50 55 60
 5 Thr Ala Ile Ser Thr Ser Pro Asp Leu Gln Trp Leu Val Gln Pro Ala
 65 70 75 80
 Leu Val Ser Ser Val Ala Pro Ser Gln Thr Arg Ala Pro His Pro Phe
 85 90 95
 10 Gly Val Pro Ala Pro Ser Ala Gly Ala Tyr Ser Arg Ala Gly Val Val
 100 105 110
 Lys Thr Met Thr Gly Gly Arg Ala Gln Ser Ile Gly Arg Arg Gly Lys
 115 120 125
 15 Val Glu Gln Leu Ser Pro Glu Glu Glu Lys Arg Arg Ile Arg Arg
 130 135 140
 Glu Arg Asn Lys Met Ala Ala Ala Lys Cys Arg Asn Arg Arg Arg Glu
 145 150 155 160
 20 Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Leu Glu Asp Glu Lys
 165 170 175
 Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys
 180 185 190
 25 Leu Glu Phe Ile Leu Ala Ala His Arg Pro Ala Cys Lys Ile Pro Asp
 195 200 205
 Asp Leu Gly Phe Pro Glu Glu Met Ser Val Ala Ser Leu Asp Leu Thr
 210 215 220
 30 Gly Gly Leu Pro Glu Val Ala Thr Pro Glu Ser Glu Glu Ala Phe Thr
 225 230 235 240
 Leu Pro Leu Leu Asn Asp Pro Glu Pro Lys Pro Ser Val Glu Pro Val
 245 250 255
 Lys Ser Ile Ser Ser Met Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe
 260 265 270
 35 Leu Phe Pro Ala Ser Ser Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser
 275 280 285
 Val Pro Asp Met Asp Leu Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu
 290 295 300
 40 Pro Leu His Ser Gly Ser Leu Gly Met Gly Pro Met Ala Thr Glu Leu
 305 310 315 320
 Glu Pro Leu Cys Thr Pro Val Val Thr Cys Thr Pro Ser Cys Thr Ala
 325 330 335
 45 Tyr Thr Ser Ser Phe Val Phe Thr Tyr Pro Glu Ala Asp Ser Phe Pro
 340 345 350
 Ser Cys Ala Ala Ala His Arg Lys Gly Ser Ser Ser Asn Glu Pro Ser
 355 360 365
 50 Ser Asp Ser Leu Ser Ser Pro Thr Leu Leu Ala Leu
 370 375 380

5 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 49 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGCACTGAGG TCAGGGGTGG GGAAGCCCAG GGCTGGGAT TCCCCATCT

49

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: Yeda Research and Development Co., Ltd.
- (B) STREET: P.O. Box 95
- (C) CITY: Rehovot
- (E) COUNTRY: Israel
- (F) POSTAL CODE (ZIP): 76100

10

(ii) TITLE OF INVENTION: Anti-Metastatic Vaccine

(iii) NUMBER OF SEQUENCES: 8

15

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

20

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: EP 93 11 7519.4

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 968,415
- (B) FILING DATE: 29-OCT-1992

25

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3135 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: cDNA

35

(ix) FEATURE:

- (A) NAME/KEY: mRNA
- (B) LOCATION: 1..3135

40

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 917..1918

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

45

CTGAGTGTGC GAGAGACAGC CTGGCAGGAG AGCGCTCAGG CAGACAGACA GACAGACGGA	60
CGGACTTGGC CAACCCGGTC GGCGCGGAC TCCGGACTGT TCATCCGTTT GTCTTCATTT	120
TCTCACCAAC TGCTTGGATC CAGCGCCCGC GGCTCCTGCA CCCGTATTTT GGGGAGCATT	180
TGGAGAGTCC CTTCTCCCGC CTTCCACGGA GAAGAAGCTC ACAAGTCCGG GCGCTGCTGA	240

50

EP 0 599 077 A2

	CAGCATCGAG AGCGGGCTCCC GACCGCGCGA GGAAATAGGC GAGCGGCTAC CGGCCAGCAA	300
	CTTTCCTGAC CCAGAGGACC GGTAACAAGT GGCCGGGAGC GAACTTTGC AAATCTCTTC	360
5	TGCGCCTTAA GGCTGCCACC GAGACTGTAA AGAAAAGGGA GAAGAGGAAC CTATACTCAT	420
	ACCAGTTCGC ACAGCGGCT GAAGTTGGC GAGCGCTAGC CGCGGCTGCC TAGCGTCCCC	480
	CTCCCCCTCA CAGCGGAGGA GGGGACAGTT GTTGGAGGCC GGGCGGCAGA GCCCGATCGC	540
10	GGGCTTCCAC CGAGAATTCC GTGACGACTG GTCAGCACCG CCGGAGAGCC GCTGTIGCTG	600
	GGACTGGTCT GCGGGCTCCA AGGAACCGCT GCTCCCCGAG AGCGCTCCGT GAGTGACCGC	660
	GACTTTCAA AGCTCGGCAT CGCGCGGGAG CCTACCAAACG TGAGTGCTAG CGGAGTCTTA	720
15	ACCCCTGCGCT CCCTGGAGCG AACTGGGAG GAGGGCTCAG GGGGAAGCAC TGCCGTCTGG	780
	AGCGCACGCT CCTAAACAAA CTTTGTACAGAAGCAGGGAG CGCGCGGGTA TCCCCCGCT	840
	TCCCGCGCG CTGTTGCGGC CCCGAAACTT CTGCGCACAG CCCAGGCTAA CCCCGCGTGA	900
20	AGTGACGGAC CGTTCT ATG ACT GCA AAG ATG GAA ACG ACC TTC TAC GAC Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp	949
	1 5 10	
	GAT GCC CTC AAC GCC TCG TTC CTC CAG TCC GAG AGC GGT GCC TAC GGC Asp Ala Leu Asn Ala Ser Phe Leu Gln Ser Glu Ser Gly Ala Tyr Gly	997
	15 20 25	
25	TAC AGT AAC CCT AAG ATC CTA AAA CAG AGC ATG ACC TTG AAC CTG GCC Tyr Ser Asn Pro Lys Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala	1045
	30 35 40	
30	GAC CCG GTG GGC AGT CTG AAG CCG CAC CTC CGC GCC AAG AAC TCG GAC Asp Pro Val Gly Ser Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp	1093
	45 50 55	
	CTT CTC ACG TCG CCC GAC GTC GGG CTG CTC AAG CTG GCG TCG CCG GAG Leu Leu Thr Ser Pro Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu	1141
	60 65 70 75	
35	CTG GAG CGC CTG ATC ATC CAG TCC AGC AAT GGG CAC ATC ACC ACT ACA Leu Glu Arg Leu Ile Ile Gln Ser Ser Asn Gly His Ile Thr Thr Thr	1189
	80 85 90	
40	CCG ACC CCC ACC CAG TTC TTG TGC CCC AAG AAC GTG ACC GAC GAG CAG Pro Thr Pro Thr Gln Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln	1237
	95 100 105	
	GAG GGC TTC GCC GAG GGC TTC GTG CGC GCC CTG GCT GAA CTG CAT AGC Glu Gly Phe Ala Glu Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser	1285
	110 115 120	
45	CAG AAC ACG CTT CCC AGT GTC ACC TCC GCG GCA CAG CCG GTC AGC GGG Gln Asn Thr Leu Pro Ser Val Thr Ser Ala Ala Gln Pro Val Ser Gly	1333
	125 130 135	

EP 0 599 077 A2

	GCG GGC ATG GTG GCT CCC GCG GTG GCC TCA GTA GCA GGC GCT GGC GGC Ala Gly Met Val Ala Pro Ala Val Ala Ser Val Ala Gly Ala Gly Gly 140 145 150 155	1381
5	GGT GGT GGC TAC AGC GCC AGC CTG CAC AGT GAG CCT CCG GTC TAC GCC Gly Gly Gly Tyr Ser Ala Ser Leu His Ser Glu Pro Pro Val Tyr Ala 160 165 170	1429
10	AAC CTC AGC AAC TTC AAC CCG GGT GCG CTG AGC AGC GGC GGT GGG GCG Asn Leu Ser Asn Phe Asn Pro Gly Ala Leu Ser Ser Gly Gly Gly Ala 175 180 185	1477
	CCC TCC TAT GGC GCG GCC GGG CTG GCC TTT CCC TCG CAG CCG CAG CAG Pro Ser Tyr Gly Ala Ala Gly Leu Ala Phe Pro Ser Gln Pro Gln Gln 190 195 200	1525
15	CAG CAG CAG CCG CCT CAG CCG CCG CAC CAC TTG CCC CAA CAG ATC CCG Gln Gln Gln Pro Pro Gln Pro Pro His His Leu Pro Gln Gln Ile Pro 205 210 215	1573
20	GTG CAG CAC CCG CGG CTG CAA GCC CTG AAG GAA GAG CCG CAG ACC GTG Val Gln His Pro Arg Leu Gln Ala Leu Lys Glu Glu Pro Gln Thr Val 220 225 230 235	1621
	CCG GAG ATG CCG GGA GAG ACG CCG CCC CTG TCC CCT ATC GAC ATG GAG Pro Glu Met Pro Gly Glu Thr Pro Pro Leu Ser Pro Ile Asp Met Glu 240 245 250	1669
25	TCT CAG GAG CGG ATC AAG GCA GAG AGG AAG CGC ATG AGG AAC CGC ATT Ser Gln Glu Arg Ile Lys Ala Glu Arg Lys Arg Met Arg Asn Arg Ile 255 260 265	1717
30	GCC GCC TCC AAG TGC CGG AAA AGG AAG CTG GAG CGG ATC GCT CGG CTA Ala Ala Ser Lys Cys Arg Lys Arg Lys Leu Glu Arg Ile Ala Arg Leu 270 275 280	1765
	GAG GAA AAA GTG AAA ACC TTG AAA GCG CAA AAC TCC GAG CTG GCA TCC Glu Glu Lys Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser 285 290 295	1813
35	ACG GCC AAC ATG CTC AGG GAA CAG GTG GCA CAG CTT AAG CAG AAA GTC Thr Ala Asn Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val 300 305 310 315	1861
40	ATG AAC CAC GTT AAC AGT GGG TGC CAA CTC ATG CTA ACG CAG CAG TTG Met Asn His Val Asn Ser Gly Cys Gln Leu Met Leu Thr Gln Gln Leu 320 325 330	1909
	CAA ACG TTT TGAGAACAGA CTGTCAGGGC TGAGGGCAA TGGAAGAAAA Gln Thr Phe	1958
45	AAAATAACAG AGACAAACTT GAGAACTTGA CTGGTTGCGA CAGAGAAAAA AAAAGTGTCC GAGTACTGAA GCCAAGGGTA CACAAGATGG ACTGGGTTGC GACCTGACGG CGCCCCCAGT GTGCTGGAGT GGGAAAGGACG TGGCGCGCCT GGCTTGGCG TGGAGCCAGA GAGCAGCGGC CTATTGGCCG GCAGACTTTG CGGACGGGCT GTGCCCGCGC GCGACCAGAA CGATGGACTT	2018 2078 2138 2198

5	TTCGTTAACAA	TTGACCAAGA	ACTGCATGGA	CCTAACATTC	GATCTCATTC	AGTATTAAAG	2258
	GGGGGTGGGA	GGGGTTACAA	ACTGCAATAG	AGACTGTAGA	TTGCTTCTGT	AGTGCTCCTT	2318
	AACACAAAGC	AGGGAGGGCT	GGGAAGGGGG	GGAGGCTTGT	AAGTGCCAGG	CTAGACTGCA	2378
	GATGAACCTCC	CCTGGCCTGC	CTCTCTCAAC	TGTGTATGTA	CATATATATT	TTTTTTTAAT	2438
10	TTGATGAAAG	CTGATTACTG	TCAATAAACAA	GCTTCCTGCC	TTTGTAAAGTT	ATTCCATGTT	2498
	TGTTTGTTC	GGTGTCTGC	CCAGTGTTC	TAAATAAGAG	ATTTGAAGCA	TTCTGAGTTT	2558
	ACCATTTGTA	ATAAAAGTATA	TAATTTTTT	ATGTTTTGTT	TCTGAAAATT	TCCAGAAAGG	2618
	ATATTTAAGA	AAATACAATA	AACTATTGAA	AAGTAGCCCC	CAACCTCTTT	GCTGCATTAT	2678
15	CCATAGATAA	TGATAGCTAG	ATGAAGTGAC	AGCTGAGTGC	CCCCAATATA	CTAGGGTGAA	2738
	AGCTGTGTCC	CCTGTCTGAT	TTGTAGGAAT	AGATACCCCTG	CATGCTATCA	TTGGCTCATA	2798
	CTCTCTCCCC	CGGCAACACA	CAAGTCCAGA	CTGTACACCA	GAAGATGGTG	TGGTGTTC	2858
20	TAAGGCTGGA	AGAAGGGCTG	TTGCAAGGGG	AGAGGGTCAG	CCCGCTGGAA	AGCAGACACT	2918
	TTGGTTGAAA	GCTGTATGAA	GTGGCATGTG	CTGTGATCAT	TTATAATCAT	AGGAAAGATT	2978
	TAGTAATTAG	CTGTTGATTC	TCAAAGCAGG	GACCCATGGA	AGTTTTAAC	AAAAGGTGTC	3038
25	TCCTTCCAAC	TTTGAATCTG	ACAACCTCTA	GAAAAAGATG	ACCTTGCTT	GTGCATATTT	3098
	ATAATAGCGT	TCGTTATCAC	AATAAATGTA	TTCAAAT			3135

(2) INFORMATION FOR SEQ ID NO: 2:

30	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 334 amino acids
	(B) TYPE: amino acid
	(D) TOPOLOGY: linear
35	(ii) MOLECULE TYPE: protein
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
	Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp Asp Ala Leu Asn Ala
	1 5 10 15
40	Ser Phe Leu Gln Ser Glu Ser Gly Ala Tyr Gly Tyr Ser Asn Pro Lys
	20 25 30
	Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala Asp Pro Val Gly Ser
	35 40 45
45	Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp Leu Leu Thr Ser Pro
	50 55 60
	Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu Leu Glu Arg Leu Ile
	65 70 75 80

Ile Gln Ser Ser Asn Gly His Ile Thr Thr Thr Pro Thr Pro Thr Gln
 85 90 95
 5 Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln Glu Gly Phe Ala Glu
 100 105 110
 Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser Gln Asn Thr Leu Pro
 115 120 125
 10 Ser Val Thr Ser Ala Ala Gln Pro Val Ser Gly Ala Gly Met Val Ala
 130 135 140
 Pro Ala Val Ala Ser Val Ala Gly Ala Gly Gly Gly Gly Tyr Ser
 145 150 155 160
 15 Ala Ser Leu His Ser Glu Pro Pro Val Tyr Ala Asn Leu Ser Asn Phe
 165 170 175
 Asn Pro Gly Ala Leu Ser Ser Gly Gly Ala Pro Ser Tyr Gly Ala
 180 185 190
 20 Ala Gly Leu Ala Phe Pro Ser Gln Pro Gln Gln Gln Gln Pro Pro
 195 200 205
 Gln Pro Pro His His Leu Pro Gln Gln Ile Pro Val Gln His Pro Arg
 210 215 220
 25 Leu Gln Ala Leu Lys Glu Glu Pro Gln Thr Val Pro Glu Met Pro Gly
 225 230 235 240
 Glu Thr Pro Pro Leu Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile
 245 250 255
 30 Lys Ala Glu Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys
 260 265 270
 Arg Lys Arg Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys
 275 280 285
 35 Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu
 290 295 300
 Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Asn
 40 305 310 315 320
 Ser Gly Cys Gln Leu Met Leu Thr Gln Gln Leu Gln Thr Phe
 325 330

(2) INFORMATION FOR SEQ ID NO: 3:

45

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3622 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- 50 (ii) MOLECULE TYPE: cDNA

55

(ix) FEATURE:
 (A) NAME/KEY: mRNA
 (B) LOCATION: 287..3622

5 (ix) FEATURE:
 (A) NAME/KEY: mRNA
 (B) LOCATION: 289..3622

10 (ix) FEATURE:
 (A) NAME/KEY: mRNA
 (B) LOCATION: 293..3622

15 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1261..2253

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CCCCGGGAGG	GGACCGGGGA	ACAGAGGGCC	GAGAGGCGTG	CGGCAGGGGG	GAGGGTAGGA	60
GAAAAGAAGGG	CCCGACTGTA	GGAGGGCAGC	GGAGCATTAC	CTCATCCCGT	GAGCCTCCGC	120
20 GGGCCCAGAG	AAGAATCTTC	TAGGGTGGAG	TCTCCATGGT	GACGGGCGGG	CCCGCCCCCC	180
TGAGAGCGAC	GCGAGCCAAT	GGGAAGGCCT	TGGGGTGACA	TCATGGGCTA	TTTTTAGGGG	240
TTGACTGGTA	GCAGATAAGT	GTTGAGCTCG	GGCTGGATAA	GGGCTCAGAG	TTGCACTGAG	300
25 TGTGGCTGAA	GCAGCGAGGC	GGGAGTGGAG	GTGCCGGAG	TCAGGCAGAC	AGACAGACAC	360
AGCCAGCCAG	CCAGGTCGGC	AGTATAGTCC	GAATGCAAA	TCTTATTTTC	TTTCACCTT	420
CTCTCTAACT	GCCCAGAGCT	AGCGCCTGTG	GCTCCGGGC	TGGTGGTTCG	GGAGTGTCCA	480
30 GAGAGCCTTG	TCTCCAGCCG	GCCCCGGGAG	GAGAGCCCTG	CTGCCCAGGC	GCTGTTGACA	540
GCGGCGGAAA	GCAGCGGTAC	CCCACGCGCC	CGCCGGGGGA	CGTCGGCGAG	CGGCTGCAGC	600
AGCAAAGAAC	TTTCCCGGCG	GGGAGGACCG	GAGACAAGTG	GCAGAGTCCC	GGAGCGAACT	660
35 TTTGCAAGCC	TTTCCTGCGT	CTTAGGCTTC	TCCACGGCGG	TAAAGACCAG	AAGGCGCGG	720
AGAGCCACGC	AAGAGAAGAA	GGACGTGCGC	TCAGCTTCGC	TCGGACCGGT	TGTTGAACCTT	780
GGGCGAGCGC	GAGCCGCGGC	TGCCGGGCGC	CCCCTCCCCC	TAGCAGCGGA	GGAGGGACA	840
40 AGTCGTCGGA	GTCCGGCGG	CCAAGACCCG	CCGCCGGCCG	GCCACTGCAG	GGTCCGCACT	900
GATCCGCTCC	GCGGGGAGAG	CCGCTGCTCT	GGGAAGTGAG	TTCGCCTGCG	GACTCCGAGG	960
AACCGCTGCG	CCCGAAGAGC	GCTCAGTGAG	TGACCGCGAC	TTTTCAAAGC	CGGGTAGCGC	1020
45 GCGCGAGTCG	ACAAGTAAGA	GTGCGGGAGG	CATCTTAATT	AACCCCTGCGC	TCCCTGGAGC	1080
GAGCTGGTGA	GGAGGGCGCA	GCGGGGACGA	CAGCCAGCGG	GTGCGTGCGC	TCTTAGAGAA	1140
ACTTCCCTG	TCAAAGGCTC	CGGGGGCGC	GGGTGTCCCC	CGCTTGCCAG	AGCCCTGTTG	1200

EP 0 599 077 A2

	CGGCCCCGAA ACTTGTGCGC GCACGCCAAA CTAACCTCAC GTGAAGTGAC GGACTGTTCT	1260
5	ATG ACT GCA AAG ATG GAA ACG ACC TTC TAT GAC GAT GCC CTC AAC GCC Met Thr Ala Lys Met Glu Thr Thr Phe Tyr Asp Asp Ala Leu Asn Ala 1 5 10 15	1308
	TCG TTC CTC CCG TCC GAG AGC GGA CCT TAT GGC TAC AGT AAC CCC AAG Ser Phe Leu Pro Ser Glu Ser Gly Pro Tyr Gly Tyr Ser Asn Pro Lys 20 25 30	1356
10	ATC CTG AAA CAG AGC ATG ACC CTG AAC CTG GCC GAC CCA GTG GGG AGC Ile Leu Lys Gln Ser Met Thr Leu Asn Leu Ala Asp Pro Val Gly Ser 35 40 45	1404
15	CTG AAG CCG CAC CTC CGC GCC AAG AAC TCG GAC CTC CTC ACC TCG CCC Leu Lys Pro His Leu Arg Ala Lys Asn Ser Asp Leu Leu Thr Ser Pro 50 55 60	1452
	GAC GTG GGG CTG CTC AAG CTG GCG TCG CCC GAG CTG GAG CGC CTG ATA Asp Val Gly Leu Leu Lys Leu Ala Ser Pro Glu Leu Glu Arg Leu Ile 65 70 75 80	1500
20	ATC CAG TCC AGC AAC GGG CAC ATC ACC ACC ACG CCG ACC CCC ACC CAG Ile Gln Ser Ser Asn Gly His Ile Thr Thr Thr Pro Thr Pro Thr Gln 85 90 95	1548
25	TTC CTG TGC CCC AAG AAC GTG ACA GAT GAG CAG GAG GGG TTC GCC GAG Phe Leu Cys Pro Lys Asn Val Thr Asp Glu Gln Glu Gly Phe Ala Glu 100 105 110	1596
	GGC TTC GTG CGC GCC CTG GCC GAA CTG CAC AGC CAG AAC ACG CTG CCC Gly Phe Val Arg Ala Leu Ala Glu Leu His Ser Gln Asn Thr Leu Pro 115 120 125	1644
30	AGC GTC ACG TCG GCG GCG CAG CCG GTC AAC GGG GCA GGC ATG GTG GCT Ser Val Thr Ser Ala Ala Gln Pro Val Asn Gly Ala Gly Met Val Ala 130 135 140	1692
	CCC GCG GTA GCC TCG GTG GCA GGG GGC AGC GGC AGC GGC GGC TTC AGC Pro Ala Val Ala Ser Val Ala Gly Gly Ser Gly Gly Phe Ser 145 150 155 160	1740
35	GCC AGC CTG CAC AGC GAG CCG CCG GTC TAC GCA AAC CTC AGC AAC TTC Ala Ser Leu His Ser Glu Pro Pro Val Tyr Ala Asn Leu Ser Asn Phe 165 170 175	1788
40	AAC CCA GGC GCG CTG AGC AGC GGC GGC GGG GCG CCC TCC TAC GGC GCG Asn Pro Gly Ala Leu Ser Ser Gly Gly Ala Pro Ser Tyr Gly Ala 180 185 190	1836
	GCC GGC CTG GCC TTT CCC GCG CAA CCC CAG CAG CAG CAG CAG CCG CCG Ala Gly Leu Ala Phe Pro Ala Gln Pro Gln Gln Gln Pro Pro 195 200 205	1884
45	CAC CAC CTG CCC CAG CAG ATG CCC GTG CAG CAC CCG CGG CTG CAG GCC His His Leu Pro Gln Gln Met Pro Val Gln His Pro Arg Leu Gln Ala 210 215 220	1932

EP 0 599 077 A2

CTG AAG GAG GAG CCT CAG ACA GTG CCC GAG ATG CCC GGC GAG ACA CCG	1980
Leu Lys Glu Glu Pro Gln Thr Val Pro Glu Met Pro Gly Glu Thr Pro	
225 230 235 240	
5 CCC CTG TCC CCC ATC GAC ATG GAG TCC CAG GAG CGG ATC AAG GCG GAG	2028
Pro Leu Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile Lys Ala Glu	
245 250 255	
10 AGG AAG CGC ATG AGG AAC CGC ATC GCT GCC TCC AAG TGC CGA AAA AGG	2076
Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys Arg Lys Arg	
260 265 270	
15 AAG CTG GAG AGA ATC GCC CGG CTG GAG GAA AAA GTG AAA ACC TTG AAA	2124
Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys	
275 280 285	
20 15 GCT CAG AAC TCG GAG CTG GCG TCC ACG GCC AAC ATG CTC AGG GAA CAG	2172
Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Gln	
290 295 300	
GTG GCA CAG CTT AAA CAG AAA GTC ATG AAC CAC GTT AAC AGT GGG TGC	2220
Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Asn Ser Gly Cys	
305 310 315 320	
25 CAA CTC ATG CTA ACG CAG CAG TTG CAA ACA TTT TGAAGAGAGA CCGTCGGGG	2273
Gln Leu Met Leu Thr Gln Gln Leu Gln Thr Phe	
325 330	
25 CTGAGGGCA ACGAAGAAAA AAAATAACAC AGAGAGACAG ACTTGAGAAC TTGACAAGTT	2333
GCGACGGAGA GAAAAAAAGAA GTGTCCGAGA ACTAAAGCCA AGGGTATCCA AGTTGGACTG	2393
GGTCGGTCT GACGGCGCCC CCAGTGTGCA CGAGTGGAA GGACTTGGTC GCGCCCTCCC	2453
30 TTGGCGTGGA GCCAGGGAGC GGCGCCTGC GGGCTGCCCG GCTTGCAGA CGGGCTGTCC	2513
CCGCGCGAAC GGAACGTTGG ACTTCGTTA ACATTGACCA AGAACTGCAT GGACCTAAC	2573
TTCGATCTCA TTCACTATTAA AAGGGGGAG GGGGAGGGGG TTACAAACTG CAATAGAGAC	2633
TGTAGATTGC TTCTGTAGTA CTCCTTAAGA ACACAAAGCG GGGGGAGGGT TGGGGAGGGG	2693
35 CGGCACGGAGG GAGGTTGTG AGAGCGAGGC TGAGCCTACA GATGAACTCT TTCTGGCCTG	2753
CTTCGTTAA CTGTGTATGT ACATATATAT ATTTTTAAT TTGATTAAAG CTGATTACTG	2813
TCAATAAACAA GCTTCATGCC TTTGTAAGTT ATTTCTTGTGTT TGTTTGTGTT GGTATCCTGC	2873
40 CCAGTGTGT TTGTAATAA GAGATTGGA GCACTCTGAG TTTACCATTG GTAATAAAAGT	2933
ATATAATTTT TTATGTTTT GTTTCTGAAA ATTCCAGAAA GGATATTTAA GAAAATACAA	2993
TAAACTATTG GAAAGTACTC CCCTAACCTC TTTCTGCAT CATCTGTAGA TCCTAGTCTA	3053
45 TCTAGGTGGA GTTGAAAGAG TTAAGAATGC TCGATAAAAT CACTCTCAGT GCTTCTTACT	3113
ATTAAGCAGT AAAAAGTGTGTT CTCTATTAGA CTTAGAAATA AATGTACCTG ATGTACCTGA	3173
TGCTATGTCA GGCTTCATAC TCCACGCTCC CCCAGCGTAT CTATATGGAA TTGCTTACCA	3233
50	

AAGGCTAGTG	CGATGTTCA	GGAGGCTGGA	GGAAGGGGGG	TTGCAGTGG	GAGGGACAGC	3293	
CCACTGAGAA	GTCAAACATT	TCAAAGTTG	GATTGCATCA	AGTGGCATGT	GCTGTGACCA	3353	
5	TTTATAATGT	TAGAAAATTT	ACAATAGGTG	CTTATTCTCA	AAGCAGGAAT	TGGTGGCAGA	3413
TTTTACAAAA	GATGTATCCT	TCCAATTGG	AATCTTCTCT	TTGACAATT	CTAGATAAAA	3473	
AGATGGCCTT	TGTCTTATGA	ATATTTATAA	CAGCATTCTG	TCACAATAAA	TGTATTCAA	3533	
10	TACCAATAAC	AGATCTTGAA	TTGCTTCCCT	TTACTACTTT	TTTGTTCCTA	AGTTATATAC	3593
TGAAGTTTT	ATTTTAGTT	GCTGAGGTT				3622	

15 (2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 331 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met	Thr	Ala	Lys	Met	Glu	Thr	Thr	Phe	Tyr	Asp	Asp	Ala	Leu	Asn	Ala	
1				5				10				15				
25	Ser	Phe	Leu	Pro	Ser	Glu	Ser	Gly	Pro	Tyr	Gly	Tyr	Ser	Asn	Pro	Lys
				20				25				30				
30	Ile	Leu	Lys	Gln	Ser	Met	Thr	Leu	Asn	Leu	Ala	Asp	Pro	Val	Gly	Ser
				35				40				45				
35	Leu	Lys	Pro	His	Leu	Arg	Ala	Lys	Asn	Ser	Asp	Leu	Leu	Thr	Ser	Pro
				50				55				60				
40	Asp	Val	Gly	Leu	Leu	Lys	Leu	Ala	Ser	Pro	Glu	Leu	Glu	Arg	Leu	Ile
				65				70			75			80		
45	Ile	Gln	Ser	Ser	Asn	Gly	His	Ile	Thr	Thr	Pro	Thr	Pro	Thr	Gln	
				85				90				95				
50	Phe	Leu	Cys	Pro	Lys	Asn	Val	Thr	Asp	Glu	Gln	Glu	Gly	Phe	Ala	Glu
				100				105				110				
Gly	Phe	Val	Arg	Ala	Leu	Ala	Glu	Leu	His	Ser	Gln	Asn	Thr	Leu	Pro	
				115				120				125				
Ser	Val	Thr	Ser	Ala	Ala	Gln	Pro	Val	Asn	Gly	Ala	Gly	Met	Val	Ala	
				130				135				140				
45	Pro	Ala	Val	Ala	Ser	Val	Ala	Gly	Gly	Ser	Gly	Ser	Gly	Gly	Phe	Ser
				145				150				155			160	
50	Ala	Ser	Leu	His	Ser	Glu	Pro	Pro	Val	Tyr	Ala	Asn	Leu	Ser	Asn	Phe
				165				170				175				

Asn Pro Gly Ala Leu Ser Ser Gly Gly Gly Ala Pro Ser Tyr Gly Ala
180 185 190

5 Ala Gly Leu Ala Phe Pro Ala Gln Pro Gln Gln Gln Gln Pro Pro
195 200 205

His His Leu Pro Gln Gln Met Pro Val Gln His Pro Arg Leu Gln Ala
210 215 220

10 Leu Lys Glu Glu Pro Gln Thr Val Pro Glu Met Pro Gly Glu Thr Pro
225 230 235 240

Pro Leu Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile Lys Ala Glu
245 250 255

15 Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys Arg Lys Arg
260 265 270

Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys
275 280 285

20 Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Gln
290 295 300

Val Ala Gln Leu Lys Gln Lys Val Met Asn His Val Asn Ser Gly Cys
305 310 315 320

25 Gln Leu Met Leu Thr Gln Gln Leu Gln Thr Phe
325 330

(2) INFORMATION FOR SEQ ID NO: 5:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3548 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35 (ix) FEATURE:
(A) NAME/KEY: TATA_signal
(B) LOCATION: 101..106

40 (ix) FEATURE:
(A) NAME/KEY: polyA_signal
(B) LOCATION: 3493..3498

45 (ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 284..424

50 (ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1179..1430

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1836..1943

(ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 2061..2702

5 (ix) FEATURE:
 (A) NAME/KEY: precursor_RNA
 (B) LOCATION: 133..2702

10 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 425..1178

15 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 1431..1835

20 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 1944..2060

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

20	GAGTTGACGA CAGAGCGCCC GCAGAGGGCC TTGGGGCGCG CTTCCCCCCC CTTCCAGTTC	60
	CGCCCACTGGA CGTAGGAAGT CCATCCATTC ACAGCGCTTC TATAAAGGCG CCAGCTGAGG	120
	CGCCTACTAC TCCAACCGCG ACTGCAGCGA GCAACTGAGA AGACTGGATA GAGCCGGCGG	180
25	TTCCCGAAGC GAGCAGTGAC CGCGCTCCCA CCCAGCTCTG CTCTGCAGCT CCCACCAGTG	240
	TCTACCCCTG GACCCCTTGC CGGGCTTCC CCAAACCTCG ACCATGATGT TCTCGGGTTT	300
	CAACGCCGAC TACGAGGCAGT CATCCTCCCG CTGCAGTAGC GCCTCCCCGG CGGGGACAG	360
30	CCTTCCTAC TACCATTCCC CAGCCGACTC CTTCTCCAGC ATGGGCTCTC CTGTCAACAC	420
	ACAGGTGAGT TTGGCTTTGT GTAGCCGCCA GGTCCGCGCT GAGGGTCGCC GTGGAGGAGA	480
	CACTGGGTG TGACTCGAG GGGCGGGGG GTCTTCCTTT TTCGCTCTGG AGGGAGACTG	540
35	GCGCGGTCAAG AGCAGCCTTA GCCTGGGAAC CCAGGACTTG TCTGAGCGCG TGCACACTTG	600
	TCATAGTAAG ACTTAGTGAC CCCTTCCCGC GCGGCAGGTT TATTCTGAGT GGCCTGCCTG	660
	CATTCTTCTC TCGGCCGACT TGTTTCTGAG ATCAGCCGGG GCCAACAAAGT CTCGAGCAAA	720
40	GAGTCGCTAA CTAGAGTTG GGAGGGCGCA AACCGCGGC ATCCCCCCTC CGGGGGCAGC	780
	CTGGAGCAGG GAGGAGGGAG GAGGGAGGAG GGTGCTGCGG GCGGGTGTGT AAGGCAGTTT	840
	CATTGATAAA AAGCGAGTTC ATTCTGGAGA CTCCGGAGCA GCGCCTGCGT CAGCGCAGAC	900
45	GTCAGGGATA TTTATAACAA ACCCCCTTTC GAGCGAGTGA TGCGAAGGG ATAACGGGAA	960
	CGCAGCAGTA GGATGGAGGA GAAAGGCTGC GCTGCGGAAT TCAAGGGAGG ATATTGGGAG	1020
	AGCTTTTATC TCCGATGAGG TGCATACAGG AAGACATAAG CAGTCTCTGA CCGGAATGCT	1080

50

55

EP 0 599 077 A2

5	TCTCTCTCCC TGCTTCATGC GACACTAGGG CCACTTGCTC CACCTGTGTC TGGAACCTCC	1140
	TCGCTCACCT CCGCTTCCT CTTTTGTTT TGTTTCAGGA CTTTGCGCA GATCTGTCCG	1200
	TCTCTAGTGC CAACTTTATC CCCACGGTGA CAGCCATCTC CACCAGCCA GACCTGCAGT	1260
	GGCTGGTGC GCCCACTCTG GTCTCCTCCG TGGCCCCATC GCAGACCAGA GCGCCCCATC	1320
10	CTTACGGACT CCCCACCCAG TCTGCTGGGG CTTACGCCAG AGCGGGAATG GTGAAGACCG	1380
	TGTCAGGAGG CAGAGCCAG AGCATCGGCA GAAGGGGCAA AGTAGACCG AGTACGACCA	1440
	ATTCTGGACC TTTGTGGCT GGGGGGGGGG GGGGGGGCGG AGACTGACGC ACAGACCACA	1500
	CAACAGAGAA GGGACGCTAC TGACTGCCTC TCCTGACCAG GAGCTGTGGC TGCTAGCCCT	1560
15	TTCCCTCCCT TGTCAGATTT TGACAGTTGG ACCCAAGACA AACTCTAGAC AGTTTCCCTG	1620
	ACAGCTTCCT ACCTCATTCT CTAGCCGGGG AGCTTCTTG TTCCCTGCT AAAGATCTCA	1680
	CTTTAAATGC AAATCACACT CTGCCTGCCA ACTGCAGGTT AGAAAAACTG CTTCACCGAG	1740
20	AGGTGCGGGT GCTGTAGGAG CCAGTTCAC TGGGGTGAUT GAATGGAGGT GACACTAGAC	1800
	AACCTTAACG GAATGTTGGT CCTTTCTTC TATAGCTATC TCCTGAAGAG GAAGAGAAC	1860
	GGAGAATCCG AAGGGAACGG AATAAGATGG CTGCAGCCAA GTGCCGGAAT CGGAGGAGGG	1920
25	AGCTGACAGA TACACTCCAA GCGTAGGTT GAACCAGCTG CTGCTCCTGA AACTTTATTA	1980
	AAGTTGGAGC TTGGGACTAT GGGCGCAGGG TCCTTGAGCA TGCCCGTGT TTATGCTTTC	2040
	TTATATCTCT CCCTATGCAG GAGACAGATC AACTTGAAGA TGAGAAGTCT GCGTTGCAGA	2100
	CTGAGATTGC CAATCTGCTG AAAGAGAAGG AAAAAGTGA GTTTATTTG GCAGCCCACC	2160
30	GACCTGCCTG CAAGATCCCC GATGACCTTG GCTTCCCAGA GGAGATGTCT GTGGCCTCCC	2220
	TGGATTTGAC TGGAGGTCTG CCTGAGGCTT CCACCCAGA GTCTGAGGAG GCCTTCACCC	2280
	TGCCCCTTCT CAACGACCCCT GAGCCCAAGC CATCCTTGA GCCAGTCAAG AGCATCAGCA	2340
35	ACGTGGAGCT GAAGGCAGAA CCCTTGATG ACTTCTTGT TCCGGCATCA TCTAGGCCCA	2400
	GTGGCTCAGA GACCTCCCGC TCTGTGCCAG ATGTGGACCT GTCCGGTTCC TTCTATGCAG	2460
	CAGACTGGGA GCCTCTGCAC AGCAATTCT TGGGGATGGG GCCCATGGTC ACAGAGCTGG	2520
40	AGCCCCCTGTG TACTCCCGTG GTCACCTGTA CTCCGGCTG CACTACTTAC ACGTCTTCCCT	2580
	TTGTCTTCAC CTACCCCTGAA GCTGACTCCT TCCCAAGCTG TGCCGCTGCC CACCGAAAGG	2640
	GCAGCAGCAG CAACGAGCCC TCCTCCGACT CCCTGAGCTC ACCCACGCTG CTGGCCCTGT	2700
45	GAGCAGTCAG AGAAGGCAAG GCAGCCGGCA TCCAGACGTG CCACTGCCCG AGCTGGTGCA	2760
	TTACAGAGAG GAGAAACACG TCTTCCCTCG AAGGTTCCCG TCGACCTAGG GAGGACCTTA	2820

50

55

5	CTCTGGTCGTG AAACACACCA GGCTGTGGGC CTCAGGACT TGCAAGGCATC CACATCTGGC	2880
	CTCCAGTCCT CACCTCTTCC AGAGATGTAG CAAAAACAAA ACAAAACAAA ACAAAAAACC	2940
	GCATGGAGTG TGTTGTCCT AGTGACACCT GAGAGCTGGT AGTTAGTAGA GCATGTGAGT	3000
	CAAGGCCTGG TCTGTGTCTC TTTCTCTTT CTCCTTAGTT TTCTCATAGC ACTAACTAAT	3060
	CTGTTGGGTT CATTATTGGA ATTAACCTGG TGCTGGATTG TATCTAGTGC AGCTGATTTT	3120
10	AACAATACCT ACTGTGTTCC TGGCAATAGC GTGTTCCAAT TAGAAACGAC CAATATTAAA	3180
	CTAAGAAAAG ATAGGACTTT ATTTTCCAGT AGATAGAAAT CAATAGCTAT ATCCATGTAC	3240
	TGTTAGTCCTT CAGCGTCAAT GTTCATTGTC ATGTTACTGA TCATGCATTG TCGAGGTGGT	3300
15	CTGAATGTTG TGACATTAAC AGTTTCCAT GAAAACGTTT TTATTGTGTT TTCAATTAT	3360
	TTATTAAGAT GGATTCTCAG ATATTTATAT TTTTATTTA TTTTTCTA CCCTGAGGTC	3420
	TTTCGACATG TGGAAAGTGA ATTTGAATGA AAAATTTAA GCATTGTTG CTTATTGTT	3480
20	CAGGACATTG TCAATAAAAG CATTAAAGTT GAATGCGACC ACCTTCTTGC TCTCTTTATT	3540
	CTCAGTTT	3548

(2) INFORMATION FOR SEQ ID NO: 6:

25	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 6210 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: single
	(D) TOPOLOGY: linear
30	(ii) MOLECULE TYPE: DNA (genomic)
	(ix) FEATURE:
	(A) NAME/KEY: CDS
	(B) LOCATION: join(889..1029, 1783..2034, 2466..2573, 2688..3326)
35	(ix) FEATURE:
	(A) NAME/KEY: misc_feature
	(B) LOCATION: 402..453
	(D) OTHER INFORMATION: /note= "transcriptional activator
40	region"
	(ix) FEATURE:
	(A) NAME/KEY: prim_transcript
	(B) LOCATION: 734..3329
45	(ix) FEATURE:
	(A) NAME/KEY: exon
	(B) LOCATION: 889..1029
	(D) OTHER INFORMATION: /note= "c-fos protein, exon1"
50	(ix) FEATURE:
	(A) NAME/KEY: intron

(B) LOCATION: 1030..1782
 (D) OTHER INFORMATION: /note= ""c-fos, intron A""

5 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 1783..2034

10 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 2035..2465

15 (ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 2466..2573

20 (ix) FEATURE:
 (A) NAME/KEY: intron
 (B) LOCATION: 2574..2687

(ix) FEATURE:
 (A) NAME/KEY: exon
 (B) LOCATION: 2688..3329

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCAGGAACAG	TGCTAGTATT	GCTCGAGCCC	GAGGGCTGGA	GGTTAGGGGA	TGAAGGTCTG	60
CTTCCACGCT	TTGCACTGAA	TTAGGGCTAG	AATTGGGGAT	GGGGGTAGGG	GCGCATTCTC	120
25 TCGGGAGCCG	AGGCTTAAGT	CCTCGGGGTC	CTGTACTCGA	TGCCGTTCT	CCTATCTCTG	180
AGCCTCAGAA	CTGTCTTCAG	TTTCCGTACA	AGGGTAAAAAA	GGCGCTCTCT	GCCCCATCCC	240
30 CCCCACCTC	GGGAACAAGG	GTCCGCATTG	AACCAGGTGC	GAATGTTCTC	TCTCATTCTG	300
CGCCGTTCCC	GCCTCCCCTC	CCCCAGCCGC	GGCCCCCGCC	TCCCCCCGCA	CTGCACCCCTC	360
GGTGTGGCT	GCAGCCCCGCG	AGCAGTTCCC	GTCAATCCCT	CCCCCCTTAC	ACAGGATGTC	420
CATATTAGGA	CATCTGCGTC	AGCAGGTTTC	CACGGCTTT	CCCTGTAGCC	CTGGGGGGAG	480
35 CCATCCCCGA	AACCCCTCAT	CTTGGGGGGC	CCACGAGACC	TCTGAGACAG	GAACTGCGAA	540
ATGCTCACGA	GATTAGGACA	CGCGCCAAGG	CGGGGGCAGG	GAGCTGCGAG	CGCTGGGGAC	600
40 GCAGCCGGGC	GGCCGCAGAA	GCGCCCAGGC	CCGCGCGCCA	CCCTCTGGC	GCCACCCTGG	660
TTGAGCCCGT	GACGTTTACA	CTCATTCTATA	AAACGCTTGT	TATAAAAGCA	GTGGCTGCCG	720
CGCCTCGTAC	TCCAACCGCA	TCTGCAGCGA	GCAACTGAGA	AGCCAAGACT	GAGCCGGCGG	780
45 CCGCGGGCGCA	GCGAACGAGC	AGTGACCGTG	CTCCTACCCA	GCTCTGCTTC	ACAGCGCCCA	840
CCTGTCTCCG	CCCCTCGGCC	CCTCGCCCGG	CTTTGCCTAA	CCGCCACG	ATG ATG TTC	897
				Met	Met Phe	

1

EP 0 599 077 A2

TCG	GGC	TTC	AAC	GCA	GAC	TAC	GAG	GCG	TCA	TCC	TCC	CGC	TGC	AGC	AGC	945	
Ser	Gly	Phe	Asn	Ala	Asp	Tyr	Glu	Ala	Ser	Ser	Ser	Arg	Cys	Ser	Ser		
5						10					15						
5	GCG	TCC	CCG	GCC	GGG	GAT	AGC	CTC	TCT	TAC	TAC	CAC	TCA	CCC	GCA	993	
	Ala	Ser	Pro	Ala	Gly	Asp	Ser	Leu	Ser	Tyr	Tyr	His	Ser	Pro	Ala	Asp	
	20				25					30		35					
10	TCC	TTC	TCC	AGC	ATG	GGC	TCG	CCT	GTC	AAC	GCG	CAG	GTAAGGCTGG		1039		
	Ser	Phe	Ser	Ser	Met	Gly	Ser	Pro	Val	Asn	Ala	Gln					
	40					45											
10	CTTCCCCGTCG	CCGCGGGGCC	GGGGGCTTGG	GGTCGCGGAG	GAGGAGACAC	CGGGCGGGAC								1099			
	GCTCCAGTAG	ATGAGTAGGG	GGCTCCCTTG	TGCCTGGAGG	GAGGCTGCCG	TGGCCGGAGC								1159			
15	GGTGCCGGCT	CGGGGGCTCG	GGACTTGCTC	TGAGCGCACG	CACGCTTGCC	ATAGTAAGAA								1219			
	TTGGTTCCCC	CTTCGGGAGG	CAGGTTCGTT	CTGAGCAACC	TCTGGTCTGC	ACTCCAGGAC								1279			
	GGATCTCTGA	CATTAGCTGG	AGCAGACGTG	TCCCAAGCAC	AAACTCGCTA	ACTAGAGCCT								1339			
20	GGCTTCTTCG	GGGAGGTGGC	AGAAAGCGGC	AATCCCCCT	CCCCCGCAG	CCTGGAGCAC								1399			
	GGAGGAGGGA	TGAGGGAGGA	GGGTGCAGCG	GGCGGGTGTG	TAAGGCAGTT	TCATTGATAA								1459			
	AAAGCGAGTT	CATTCTGGAG	ACTCCGGAGC	GGCGCCTGCG	TCAGCGCAGA	CGTCAGGGAT								1519			
25	ATTTATAACA	AACCCCTTT	CAAGCAAGTG	ATGCTGAAGG	GATAACGGGA	ACGCAGCGGC								1579			
	AGGATGGAAG	AGACAGGCAC	TGCGCTGCGG	AATGCCTGGG	AGGAAAAGGG	GGAGACCTTT								1639			
	CATCCAGGAT	GAGGGACATT	TAAGATGAAA	TGTCCGTGGC	AGGATCGTTT	CTCTTCACTG								1699			
30	CTGCATGCGG	CACTGGGAAC	TCGCCCCACC	TGTGTCCCGA	ACCTGCTCGC	TCACGTCGGC								1759			
	TTTCCCCTTC	TGTTTGTTC	TAG	GAC	TTC	TGC	ACG	GAC	CTG	GCC	GTC	TCC		1809			
			Asp	Phe	Cys	Thr	Asp	Leu	Ala	Val	Ser		50	55			
35	AGT	GCC	AAC	TTC	ATT	CCC	ACG	GTC	ACT	GCC	ATC	TCG	ACC	AGT	CCG	GAC	1857
	Ser	Ala	Asn	Phe	Ile	Pro	Thr	Val	Thr	Ala	Ile	Ser	Thr	Ser	Pro	Asp	
	60					65					70						
40	CTG	CAG	TGG	CTG	GTG	CAG	CCC	GCC	CTC	GTC	TCC	TCT	GTG	GCC	CCA	TCG	1905
	Leu	Gln	Trp	Leu	Val	Gln	Pro	Ala	Leu	Val	Ser	Ser	Val	Ala	Pro	Ser	
	75				80						85						
45	CAG	ACC	AGA	GCC	CCT	CAC	CCT	TTC	GGA	GTC	CCC	GCC	CCC	TCC	GCT	GGG	1953
	Gln	Thr	Arg	Ala	Pro	His	Pro	Phe	Gly	Val	Pro	Ala	Pro	Ser	Ala	Gly	
	90				95						100						
50	GCT	TAC	TCC	AGG	GCT	GGC	GTT	GTG	AAG	ACC	ATG	ACA	GGA	GGC	CGA	GCG	2001
	Ala	Tyr	Ser	Arg	Ala	Gly	Val	Val	Lys	Thr	Met	Thr	Gly	Gly	Arg	Ala	
	105				110				115		120						
	CAG	AGC	ATT	GGC	AGG	GGC	AAG	GTG	GAA	CAG	GTGAGGA	ACT	CTAGCGTACT		2054		
	Gln	Ser	Ile	Gly	Arg	Arg	Gly	Lys	Val	Glu	Gln						
	125					130											

EP 0 599 077 A2

	CTTCCTGGGA ATGTGGGGC TGGGTGGAA GCAGCCCCG AGATGCAGGA GCCCAGTACA	2114
	GAGGATGAAG CCACTGATGG GGCTGGCTGC ACATCCGTAA CTGGGAGCCC TGGCTCCAAG	2174
5	CCCATTCCAT CCCAACTCAG ACTCTGAGTC TCACCCCTAAG AAGTACTCTC ATAGTTCTT	2234
	CCCTAAGTTT CTTACCGCAT GCTTTCAGAC TGGGCTCTTC TTTGTTCTCT TGCTGAGGAT	2294
	CTTATTTAA ATGCAAGTCA CACCTATTCT GCAACTGCAG GTCAGAAATG GTTTCACAGT	2354
10	GGGGTGCCAG GAAGCAGGGA AGCTGCAGGA GCCAGTTCTA CTGGGGTGGG TGAATGGAGG	2414
	TGATGGCAGA CACTTTACT GAATGTCGGT CTTTTTTGT GATTATTCTA G TTA TCT	2471
	Leu Ser	
15	CCA GAA GAA GAA GAG AAA AGG AGA ATC CGA AGG GAA AGG AAT AAG ATG	2519
	Pro Glu Glu Glu Glu Lys Arg Arg Ile Arg Arg Glu Arg Asn Lys Met	
	135 140 145	
	GCT GCA GCC AAA TGC CGC AAC CGG AGG AGG GAG CTG ACT GAT ACA CTC	2567
	Ala Ala Ala Lys Cys Arg Asn Arg Arg Arg Glu Leu Thr Asp Thr Leu	
20	150 155 160 165	
	CAA GCG GTAGGTACTC TGTGGTTGC TCCTTTTAA AACTTAAGGG AAAGTTGGAG	2623
	Gln Ala	
25	ATTGAGCATA AGGGCCCTTG AGTAAGACTG TGTCTTATGC TTTCTTTAT CCCTCTGTAT	2683
	ACAG GAG ACA GAC CAA CTA GAA GAT GAG AAG TCT GCT TTG CAG ACC GAG	2732
	Glu Thr Asp Gln Leu Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu	
	170 175 180	
30	ATT GCC AAC CTG CTG AAG GAG AAG GAA AAA CTA GAG TTC ATC CTG GCA	2780
	Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala	
	185 190 195	
	GCT CAC CGA CCT GCC TGC AAG ATC CCT GAT GAC CTG GGC TTC CCA GAA	2828
	Ala His Arg Pro Ala Cys Lys Ile Pro Asp Asp Leu Gly Phe Pro Glu	
35	200 205 210	
	GAG ATG TCT GTG GCT TCC CTT GAT CTG ACT GGG GGC CTG CCA GAG GTT	2876
	Glu Met Ser Val Ala Ser Leu Asp Leu Thr Gly Gly Leu Pro Glu Val	
	215 220 225 230	
40	GCC ACC CCG GAG TCT GAG GAG GCC TTC ACC CTG CCT CTC AAT GAC	2924
	Ala Thr Pro Glu Ser Glu Glu Ala Phe Thr Leu Pro Leu Leu Asn Asp	
	235 240 245	
	CCT GAG CCC AAG CCC TCA GTG GAA CCT GTC AAG AGC ATC AGC AGC ATG	2972
	Pro Glu Pro Lys Pro Ser Val Glu Pro Val Lys Ser Ile Ser Ser Met	
45	250 255 260	
	GAG CTG AAG ACC GAG CCC TTT GAT GAC TTC CTG TTC CCA GCA TCA TCC	3020
	Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe Leu Phe Pro Ala Ser Ser	
	265 270 275	

EP 0 599 077 A2

	AGG CCC AGT GGC TCT GAG ACA GCC CGC TCC GTG CCA GAC ATG GAC CTA	3068
	Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser Val Pro Asp Met Asp Leu	
280	285	290
5	TCT GGG TCC TTC TAT GCA GCA GAC TGG GAG CCT CTG CAC AGT GGC TCC	3116
	Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu Pro Leu His Ser Gly Ser	
295	300	305
	310	
10	CTG GGG ATG GGG CCC ATG GCC ACA GAG CTG GAG CCC CTG TGC ACT CCG	3164
	Leu Gly Met Gly Pro Met Ala Thr Glu Leu Glu Pro Leu Cys Thr Pro	
	315	320
	325	
	GTG GTC ACC TGT ACT CCC AGC TGC ACT GCT TAC ACG TCT TCC TTC GTC	3212
	Val Val Thr Cys Thr Pro Ser Cys Thr Ala Tyr Thr Ser Ser Phe Val	
	330	335
	340	
15	TTC ACC TAC CCC GAG GCT GAC TCC TTC CCC AGC TGT GCA GCT GCC CAC	3260
	Phe Thr Tyr Pro Glu Ala Asp Ser Phe Pro Ser Cys Ala Ala Ala His	
	345	350
	355	
20	CGC AAG GGC AGC AGC AAT GAG CCT TCC TCT GAC TCG CTC AGC TCA	3308
	Arg Lys Gly Ser Ser Asn Glu Pro Ser Ser Asp Ser Leu Ser Ser	
	360	365
	370	
	CCC ACG CTG CTG GCC CTG TGAGGGGGCA GGGAAAGGGGA GGCAGCCGGC	3356
	Pro Thr Leu Leu Ala Leu	
	375	380
25	ACCCACAAGT GCCACTGCC GAGCTGGTGC ATTACAGAGA GGAGAAACAC ATCTTCCCTA	3416
	GAGGGTTCCT GTAGACCTAG GGAGGACCTT ATCTGTGCGT GAAACACACC AGGCTGTGGG	3476
	CCTCAAGGAC TTGAAAGCAT CCATGTGTGG ACTCAAGTCC TTACCTCTTC CGGAGATGTA	3536
30	GCAAAACGCA TGGAGTGTGT ATTGTTCCCA GTGACACTTC AGAGAGCTGG TAGTTAGTAG	3596
	CATGTTGAGC CAGGCCTGGG TCTGTGTCTC TTTTCTCTT CTCCTTAGTC TTCTCATAGC	3656
	ATTAACATAAT CTATTGGTT CATTATTGGA ATTAACCTGG TGCTGGATAT TTCAAATTG	3716
35	TATCTAGTGC AGCTGATTTT ACAATAACT ACTGTGTTCC TGGCAATAGT GTGTTCTGAT	3776
	TAGAAATGAC CAATATTATA CTAAGAAAAG ATACGACTTT ATTTCTGGT AGATAGAAAT	3836
	AAATAGCTAT ATCCATGTAC TGTAGTTTT CTTCAACATC AATGTTCATT GTAATGTTAC	3896
40	TGATCATGCA TTGTTGAGGT GGCTCTGAATG TTCTGACATT AACAGTTTC CATGAAAACG	3956
	TTTTATTGTG TTTTAATT ATTATTAAG ATGGATTCTC AGATATTAT ATTATTTATT	4016
	TATTTTTTC TACCTTGAGG TCTTTGACA TGTGGAAAGT GAATTGAAAT GAAAAATTAA	4076
45	AGCATTGTT GCTTATTGTT CCAAGACATT GTCAATAAAA GCATTTAAGT TGAATGCGAC	4136
	CAACCTTGTG CTCTTTCAT TCTGGAAGTC TTGTAAGTTT CTGAAAGGTA TTATTGGAGA	4196
	CCAGTTGTC AAGAAGGGTA GCTGCTGGAG GGGGACACAC CCTCTGTCTG ATCCCTTATC	4256
50	AAAGAGGACA AGGAAACTAT AGAGCTGATT TTAGAATATT TTACAAATAC ATGCCTTCCA	4316

EP 0 599 077 A2

5	TTGGAATGCT AAGATTTCT ACTGCTTCTG GGGACGGGAA ACCGCTGTGT AACAGCTTT	4376
	GTGGGAATAC ATTTTTCTG TTTCAGTACT CGCAGGGGA AATATTAAA TTTTGTGTG	4436
	CTAATATTAA ATTCAAGATGT TTTGATCTTA AAGGAACCCCT TTAAGCAAAC AGAACCTAGC	4496
	TTTGTACAGA CTATTTAAC TTTTATTCT CACAAAATCA CGTGGAGGGT TATTCTACTT	4556
10	CAAAGATGAG CAAATTGAAG AATGGTTAGA ATAAACAAC T TCTTGATAT TCCGTTATCG	4616
	GCATTAGAAT CTTCCCTGCTC GTTATCGTAT CCAGCAGGCT GAACTGCCTC TTGATACTTG	4676
	GTTAAAAAAA ATTTTCAGGC CGGGCGCGGT GGCCCATGCC TGTAATCCTA GCACTTTGGG	4736
	AGGCCGAGGC AGCGGATCA CCTGAGGTGCG GGAGTTCGAG ACCAGCCTGA CCAACATGGA	4796
15	GAAACCCCGT CTTTACTAAA AATACAAAAT TAGCCTGGTG TGGTGGTGCA TGCCTGTAAT	4856
	CCTAGCTACT TGAGAGGCTG AGACAGGAAA ATCACTTGAA CTCGGGAGGC GGATGTTGCA	4916
	GCGAACTGAG ATTGCCCAT TGCACTCCAG CCTGGGCAAC AAGATTGAAA CTCTGTTAA	4976
20	AAAAAAAAGT TTTCACTAAT GTGTACATTT TTTTGTACTC TTTTATTCTC GAAAGGGAAAG	5036
	GAGGGCTATT GCCCTATCCC TTATTAATAA ATGCATTGTG GTTCTGGTT TCTCTAATAC	5096
	CATATGCCCT TCATTCAGTT TATAGTGGGC GGAAGTGGGG GAGAAAAAGT TGCTCAGAAA	5156
25	TCAAAAGATA TCTCAAACAG CACAAATAAT GGCTGATCGT TCTGCAAACA AAAAGTTACA	5216
	TAATAGCTCA AGAAGGAGAA GTCAACATGA CTCTGAACAA GCTTTAACTT AGAAACTTTA	5276
	TCATCTTAAG GAAGAACGTG ACCTTGTCC AGGACGTCTC TGGTAATGGG GCACTTACAC	5336
30	ACACATGCAC ACGTACAAAC CACAGGGAAA GGAGACGCC CTTCTGCCTC TGCTCGCGAG	5396
	TATCACGCAG GCACCATGCA CTATGTTTC ACACACACTG GGTGGAAGAA GAGCTTCAGC	5456
	GCCAGTCTTC TAATGTTTG GTGATAATGA AAATCACTGG GTGCTTATGG GGTGTCATAT	5516
35	TCAATCGAGT TAAAAGTTTT AATTCAAAT GACAGTTTA CTGAGGTTGA TGTTCTCGTC	5576
	TATGATATCT CTGCCCTCC CATAAAAATG GACATTTAAA AGCAACTTAC CGCTCTTAG	5636
	ATCACTCCTA TATCACACAC CACTTGGGT GCTGTTCTG CTAGACTTGT GATGACAGTG	5696
40	GCCTTAGGAT CCCTGTTGC TGTTCAAAGG GCAAATATTT TATAGCTTT AAATATACCT	5756
	AAACTAAATA CAGAATTAAAT ATAACAAACA AACACCTGGT CTGAAATAAC AAGGTGATCT	5816
	ACCTGGAAAG GAACCCAGCT GGTGGGCCAG GAGCGGTGGC TCACACCTGT AATTCCAGCA	5876
45	CTTTGGGAGG CTGAGACAGG AGGATCACTG GAGTCCAGGA GTTTGAGACC AGCCTGGGCA	5936
	ACATGGCAAA ACCCAGTGTG CTTCTGTTGT CCCAGCTACA CTACTCAGGA GGCTGAGGCA	5996
	GGAGTATGAC TTGAGCCTGG GAGGGGGAGG TTGCAGAGAA CTGATATTGC ACCACCACTG	6056

50

55

CACTCCAGCC	TGGGTGACAC	AGCAAAACCC	TATCTAAAAA	AAAAAAAAAA	AAAAAAGGAA	6116
CCCAGCTGGT	TCCTGTAGGT	GTGCAATAAT	AACAACCAGA	GGAAGAAAAG	GAAGACGATT	6176
5	TCCCAGATGA	AGAAGGGCAG	CTGGACCTTC	GGAC		6210

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 380 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Met	Met	Phe	Ser	Gly	Phe	Asn	Ala	Asp	Tyr	Glu	Ala	Ser	Ser	Arg
1					5				10					15

Cys	Ser	Ser	Ala	Ser	Pro	Ala	Gly	Asp	Ser	Leu	Ser	Tyr	Tyr	His	Ser
					20			25				30			

Pro	Ala	Asp	Ser	Phe	Ser	Ser	Met	Gly	Ser	Pro	Val	Asn	Ala	Gln	Asp
					35			40				45			

Phe	Cys	Thr	Asp	Leu	Ala	Val	Ser	Ser	Ala	Asn	Phe	Ile	Pro	Thr	Val
					50			55			60				

Thr	Ala	Ile	Ser	Thr	Ser	Pro	Asp	Leu	Gln	Trp	Leu	Val	Gln	Pro	Ala
					65			70			75			80	

Leu	Val	Ser	Ser	Val	Ala	Pro	Ser	Gln	Thr	Arg	Ala	Pro	His	Pro	Phe
					85			90			95				

Gly	Val	Pro	Ala	Pro	Ser	Ala	Gly	Ala	Tyr	Ser	Arg	Ala	Gly	Val	Val
					100			105			110				

Lys	Thr	Met	Thr	Gly	Gly	Arg	Ala	Gln	Ser	Ile	Gly	Arg	Arg	Gly	Lys
					115			120			125				

Val	Glu	Gln	Leu	Ser	Pro	Glu	Glu	Glu	Lys	Arg	Arg	Ile	Arg	Arg
					130			135			140			

Glu	Arg	Asn	Lys	Met	Ala	Ala	Ala	Lys	Cys	Arg	Asn	Arg	Arg	Glu
				145				150			155			160

Leu	Thr	Asp	Thr	Leu	Gln	Ala	Glu	Thr	Asp	Gln	Leu	Glu	Asp	Glu	Lys
					165			170			175				

Ser	Ala	Leu	Gln	Thr	Glu	Ile	Ala	Asn	Leu	Leu	Lys	Glu	Lys	Glu	Lys
					180			185			190				

Leu	Glu	Phe	Ile	Leu	Ala	Ala	His	Arg	Pro	Ala	Cys	Lys	Ile	Pro	Asp
					195			200			205				

Asp	Leu	Gly	Phe	Pro	Glu	Glu	Met	Ser	Val	Ala	Ser	Leu	Asp	Leu	Thr
					210			215			220				

50

Gly Gly Leu Pro Glu Val Ala Thr Pro Glu Ser Glu Glu Ala Phe Thr
225 230 235 240

Leu Pro Leu Leu Asn Asp Pro Glu Pro Lys Pro Ser Val Glu Pro Val
5 245 250 255

Lys Ser Ile Ser Ser Met Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe
260 265 270

Leu Phe Pro Ala Ser Ser Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser
10 275 280 285

Val Pro Asp Met Asp Leu Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu
290 295 300

Pro Leu His Ser Gly Ser Leu Gly Met Gly Pro Met Ala Thr Glu Leu
15 305 310 315 320

Glu Pro Leu Cys Thr Pro Val Val Thr Cys Thr Pro Ser Cys Thr Ala
325 330 335

Tyr Thr Ser Ser Phe Val Phe Thr Tyr Pro Glu Ala Asp Ser Phe Pro
20 340 345 350

Ser Cys Ala Ala Ala His Arg Lys Gly Ser Ser Ser Asn Glu Pro Ser
355 360 365

Ser Asp Ser Leu Ser Ser Pro Thr Leu Leu Ala Leu
25 370 375 380

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
30 (B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGCAGTGAGG TCAGGGGTGG GGAAGCCAG GGCTGGGGAT TCCCCATCT

49

40 Claims

1. Anti-tumor cellular vaccine comprising tumor cells into which *c-fos* gene (SEQ ID No:6) alone or together with *c-jun* gene (SEQ ID No:3) have been inserted.
- 45 2. An anti-tumor vaccine according to claim 1 wherein said tumor cells are human tumor cells.
3. An anti-tumor vaccine according to claim 1 or 2 wherein said tumor cells are derived from tumor cells having metastatic competence.
- 50 4. An anti-tumor vaccine according to any of claims 1 to 3 comprising human tumor cells transfected with *c-fos* gene.
5. An anti-tumor vaccine according to any of claims 1 to 3 comprising human tumor cells transfected with both *c-fos* and *c-jun* genes.
- 55 6. An anti-tumor vaccine according to claim 5 wherein the *c-fos* and *c-jun* genes have been introduced into said tumor cells on a single expression vector enabling constitutive production of the *c-fos* and *c-jun* gene products *in vivo*.

7. An anti-tumor vaccine according to claim 5 wherein the *c-fos* and *c-jun* genes have been introduced into said tumor cells on different expression vectors enabling constitutive production of the *c-fos* and *c-jun* gene products *in vivo*.
- 5 8. An anti-tumor vaccine according to claim 4 wherein *c-fos* gene has been introduced into said tumor cells on an expression vector enabling constitutive production of the *c-fos* gene product *in vivo*.
9. An anti-tumor vaccine according to any of claims 1 to 8 wherein said tumor cells are cells from a tumor from the individual to be vaccinated.
- 10 10. An anti-tumor vaccine according to any of claims 1 to 8 wherein said tumor cells are derived from individuals other than the individual to be vaccinated.
11. An anti-tumor vaccine according to any of claims 1 to 8 comprising transfected tumor cells which show increased levels of expression of MHC class I protein.
- 15 12. An anti-tumor vaccine according to any of claims 1 to 11 wherein said tumor cells have been inactivated.
- 20 13. An anti-tumor vaccine according to claim 12 wherein said tumor cells have been inactivated by treatment with gamma or X-rays and/or mitomycin C.
14. An anti-tumor vaccine according to any of claims 1 to 13 comprising from about 1×10^6 to about 1×10^9 transfected tumor cells.
- 25 15. An anti-tumor vaccine according to any of claims 1 to 14 characterized in that it is formulated as an injection.
16. An anti-tumor vaccine comprising antigens expressed by *c-fos* gene alone or together with *c-jun* genes.
- 30 17. An anti-tumor vaccine according to any of claims 1 to 16 for the treatment of a patient suffering from cancer to prevent and/or inhibit the development of metastases.
18. A method for the production of an anti-tumor vaccine according to any of claims 1 to 16 comprising the steps of:
 - 35 a) removing cells from a primary tumor of the patient by biopsy or surgery;
 - b) dispersing the cells in a medium;
 - c) inserting into said cells a vector comprising the human *c-fos* gene or the human *c-fos* and *c-jun* genes;
 - 40 d) optionally selecting the positive transflectants that show high expression of *c-fos* and MHC class I genes; and
 - e) inactivating the transflectants by gamma- or X-ray irradiation and/or treatment with mitomycin C.
- 45 19. A method of inducing MHC expression in tumor cells from endogenous genes by transfecting the tumor cells with *c-fos* or *c-fos* and *c-jun* genes.




Fig-1A




Fig-1B




Fig-1C





Fig-1D

Fig - 2 A






Fig-2B




Fig-2C




Fig - 3 A




Fig - 3 B




Fig-3 C




Fig-3 D




Fig-4A




Fig-4B




Fig-4C

EP 0 599 077 A2




Fig - 5 A




Fig - 5 B




Fig. 5c




Fig-6A




Fig-6B




Fig-6C




Fig-6D




Fig - 7